REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > O-glycoside > > Nitrogen Containing Hetero Ring > Polynucleotide (e.g., Rna, Dna, Etc.) Polynucleotide (e.g., Rna, Dna, Etc.)Polynucleotide (e.g., Rna, Dna, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027103 - Methods and compositions for silencing genes without inducing toxicity The present invention provides methods of post-transcriptional gene silencing which involve the use of a first dsRNA having substantial sequence identity to a target nucleic acid and a short, second dsRNA which inhibits dsRNA-mediated toxicity. These methods can be used to prevent or treat a disease or infection by silencing ... 02/01/07 - 20070027102 - Methods and compositions for treating macular degeneration This invention relates to methods of treating age-related macular degeneration (AMD). In particular, this invention provides methods of treating all forms of wet, age-related macular degeneration. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat wet AMD. ... 02/01/07 - 20070027101 - Methods for treating ocular neovascular diseases Disclosed herein are methods for treating ocular neovascular disease using anti-VEGF therapy in combination with a second therapy that inhibits the development of ocular neovascularization or destroys abnormal blood vessels in the eye, such as photodynamic therapy. ... 02/01/07 - 20070027100 - Use of placental growth factor for preventing or treating ischemic diseases or stroke The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in ... 02/01/07 - 20070027099 - Gene therapy of hbv infection via adeno-associated viral vector mediated long term expression of small hairpin rna (shrna) The invention provides a vector comprising an AAV-shRNA vector. The vector is preferably rAAV-151i/1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit or reduce HBV replication. ... 02/01/07 - 20070027098 - Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof The invention relates to immunostimulatory oligonucleotide compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify ... 02/01/07 - 20070027097 - Small interfering rna with improved activity Chemically modified small interfering RNAs are described. Combinations of 2′-hydroxyl substitutions on the nucleotide riboses are shown to increase the longevity and extent of target gene knockdown in mammalian cells. ... 02/01/07 - 20070027096 - Aptamers to human epidermal growth factor receptor-3 The disclosure provided herein provides compositions of nucleic acid aptamers that bind human epidermal growth factor receptor-3 and methods for their use. ... 01/25/07 - 20070021375 - Genetic modification of targeted regions of the cardiac conduction system Disclosed are compositions, methods and systems for preventing or treating cardiac dysfunction, particularly cardiac pacing dysfunction by genetic modification of cells of targeted regions of the cardiac conduction system. In particular, a bio-pacemaker composition is delivered to cardiac cells to increase the intrinsic pacemaking rate of the cells, wherein the ... 01/25/07 - 20070021374 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021373 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021372 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021371 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021370 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021369 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021368 - Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting ... 01/25/07 - 20070021367 - Modulation of socs-3 expression Compounds, compositions and methods are provided for modulating the expression of SOCS-3. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SOCS-3. Methods of using these compounds for modulation of SOCS-3 expression and for diagnosis and treatment of disease associated with expression of SOCS-3 are provided. ... 01/25/07 - 20070021366 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors ... 01/25/07 - 20070021365 - Inhibition of lysyl oxidase for treating tumor growth and diagnostics relating thereto Disclosed are methods of identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival. ... 01/25/07 - 20070021364 - Methods for genetic immunization The present invention relates to methods for delivering a genetic immunogen, comprising a nucleic acid capable of expressing an antigen, optionally complexed with a polymer. The nucleic acid is delivered to the host via hydrodynamic intravascular injection resulting in expression of an encoded antigen in extravascular cells and induction of ... 01/25/07 - 20070021363 - Genomic replacement therapy Genomic Replacement Therapy uses the human genome found in mantle dentin of a patient's tooth to affect other cells of the body. Mantle Dentin cells in the developed tooth do not reproduce, therefore the DNA is “younger”. Replacing the genome with a “younger” one will hopefully create beneficial effect to ... 01/25/07 - 20070021362 - Antisense antibacterial method and compound A method and antisense compound for inhibiting the growth of pathogenic bacterial cells are disclosed. The compound contains no more than 12 nucleotide bases and has a targeting nucleic acid sequence of no fewer than 10 bases in length that is complementary to a target sequence containing or within 10 ... 01/25/07 - 20070021361 - Methods and materials for modulating trpm2 The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPM2. The compositions comprise antisense oligonucleotides, particularly antisense oligonucleotides targeted to nucleic acids encoding TRPM2. ... 01/25/07 - 20070021360 - Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, ... 01/18/07 - 20070015724 - Prefoldin 4 in the treatment and diagnosis of cancer This invention provides methods employing prefoldin-4 (PFDN-4) nucleic acid and polypeptide sequences to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and/or for prognostic applications. Further, the invention provides methods of identifying inhibitors of PfDN-4 and methods of treating cancer by inhibiting ... 01/18/07 - 20070015723 - Antiviral oligonucleotides having a conserved g4 core sequence Modified oligonucleotides having a conserved G4 sequence and a sufficient number of flanking nucleotides to significantly inhibit the activity of a virus or phospholipase A2 or to modulate the telomere length of a chromosome are provided. G4 quartet oligonucleotide structures are also provided. Methods of prophylaxis, diagnostics and therapeutics for ... 01/18/07 - 20070015722 - Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation The present invention provides double stranded compositions that have a region that is complementary to a target nucleic acid. One of the targeting strand or the second strand comprises linked ribofuranosyl nucleosides and the other strand comprises linked modified nucleosides that have 3′-endo conformational geometry. The strands can be linked ... 01/18/07 - 20070015721 - Hiv-gag codon-optimised dna vaccines The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment ... 01/11/07 - 20070010474 - Nf-kappab oligonucleotide decoy molecules The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention ... 01/11/07 - 20070010473 - Nucleic acid ligands to integrins Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents. ... 01/11/07 - 20070010472 - Oligonucleotide compositions and their use to induce differentiation of cells The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce ... 01/11/07 - 20070010471 - Hiv dna vaccine A DNA vaccines or immunogenic composition for providing an immune response against HIV without exhibiting pathogenicity in the immunized individual because of the disruption of the ability of the DNA molecules to encode for viral proteins critical in producing pathogenicity. The DNA molecule is derived by passaging a SHIV in ... 01/11/07 - 20070010470 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 01/11/07 - 20070010469 - Gene products differentially expressed in cancerous cells iii The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer. ... 01/11/07 - 20070010468 - Methods and compositions for the inhibition of stat5 in prostate cancer cells The present invention relates to compositions and methods for the treatment of prostate cancer. In certain embodiments, the invention relates to compositions and methods for the inhibition of prostate cancer cell growth, comprising inhibiting the activity of Stat5 in prostate cancer cells. ... 01/11/07 - 20070010467 - Targeted double stranded rna mediated cell killing A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter comprising a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue. ... 01/04/07 - 20070004668 - Antisense permeation enhancers A pharmaceutical composition comprising an antisense oligonucleotide and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups. ... 01/04/07 - 20070004667 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004666 - Methods for modulating apoptotic cell death Proteinaceous transcription factors that regulate the transcription of genes and/or the translation of messenger RNA encoding proteins involved in apoptosis, such as CD95 and p53, are disclosed, together with methods for the use of such transcription factors in the modulation of apoptotic cell death. Methods for regulating apoptosis have therapeutic ... 01/04/07 - 20070004665 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004664 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004663 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 01/04/07 - 20070004662 - Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions ... 01/04/07 - 20070004661 - Antisense antiviral compound and method for treating influenza viral infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds ... 01/04/07 - 20070004660 - Synergistic modulation of flt3 kinase using alkylquinolines and alkylquinazolines where R1, R2, R3, Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3. ... 01/04/07 - 20070004659 - Method for preventing or delaying the onset of diabetes A method for preventing, delaying the onset of or treating diabetes in a patient comprising selecting a patient who is susceptible to developing diabetes, who is developing diabetes or who is diabetic and administering to the patient one or more than one dose of a pharmaceutical agent comprising a polynucleotide ... 01/04/07 - 20070004658 - Method and means for treatment of osteoarthritis The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing anabolic stimulation of chondrocytes, including cartilage formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean cartilage thickness in a ... 01/04/07 - 20070004657 - Diagnosis and treatment of kidney fibrosis and other fibrotic diseases The present invention provides methods of treatment of fibrosis by identification and isolation of polynucleotide sequences, the expression of which is altered in fibrosis. The present invention also relates to the use of these isolated polynucleotides and the polypeptides encoded thereby as probes for diagnosis, for screening of treatment modalities ... 01/04/07 - 20070004656 - Trans-sialidases obtained from trypanosoma congolense The invention relates to novel enzymes, which transfer sialic acid from a donor molecule onto an acceptor molecule (trans-sialidases). The enzymes are isolated from the protozoan Trypanosoma congolense. The invention also relates to functional equivalents of said enzymes, to the nucleic acid sequences and amino acid sequences that code for ... 01/04/07 - 20070004655 - Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors The present invention relates to the identification of a novel role of Nr-CAM in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of Nr-CAM in a number of primary tumors and cell lines derived from tumors, in addition to, the altered ... 12/28/06 - 20060293272 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/28/06 - 20060293271 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/28/06 - 20060293270 - Methods and compositions for treating ocular disorders This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease. ... 12/28/06 - 20060293269 - Antisense modulation of superoxide dismutase 1, soluble expression Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of ... 12/28/06 - 20060293268 - Antisense antiviral compounds and methods for treating foot and mouth disease An antiviral antisense composition and method for treating foot-and-mouth disease virus (FMDV) in veterinary animals is disclosed. The composition contains an antisense compound that has a sequence effective to target at least 12 contiguous bases of an FMDV RNA sequence within a region of the positive-strand genomic RNA defined by ... 12/28/06 - 20060293267 - Dual functional oligonucleotides for use as anti-viral agents The present invention is based, in part, on the discovery that endogenous mRNAs, such as viral miRNAs, can be recruited for translational repression of target mRNAs, such as viral target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means of treating viral infections, of treating diseases ... 12/28/06 - 20060293266 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and ... 12/28/06 - 20060293265 - Methods involving aldose reductase inhibitors Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of sepsis and autoimmune diseases, including Type I diabetes and rheumatoid arthritis. The invention also pertains to preventing the loss of cardiac muscle contractibility. ... 12/28/06 - 20060293264 - Stat3 decoy oligonucleotides and uses therefor A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating ... 12/28/06 - 20060293263 - Preparation for preventing contact of pathogenic matter with living organism Intermolecular mutual recognition between pathogenic matter, such as allergen group or disease-causing microbe, capable of functioning at the attachment thereof to living organism and a living organism is inhibited by the use of pectins or nucleic acids. ... 12/28/06 - 20060293262 - Inhibition of gene expression using rna interfering agents The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g., ... 12/21/06 - 20060287274 - Phosphoepoxides, method for making same and uses Cat+ is an organic or inorganic cation, n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate Tγ9δ2 lymphocytes. ... 12/21/06 - 20060287273 - Methods and reagents for inhibiting cell proliferation Methods and reagents for reducing expression of proteins involved in intracellular signalling are disclosed. Specifically, siRNA sequences are provided for reducing expression of Src, stat3, and c-myc gene products. Combination treatments are disclosed for inhibiting cell proliferative pathways, and for reducing tumor growth in breast and colon cancer. ... 12/21/06 - 20060287272 - Methods for determining specificity of rna silencing and for genetic analysis of the silenced gene or protein Methods and kits for determining the specificity of siRNAs for their targets are provided. Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene ... 12/21/06 - 20060287271 - Dinucleoside poly(borano)phosphate derivatives and uses thereof Dinucleoside poly(borano)phosphates are provided that can be useful for prevention or treatment of diseases or disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibtosis and cancer. ... 12/21/06 - 20060287270 - Methods of using redox-active surfactants to control polymer interactions The present invention provides methods utilizing redox-active surfactants to provide electrochemical control over polymer interactions. In one embodiment, the invention is directed to a transfection method using a redox-active transfection agent that preferentially promotes transfection dependent on the oxidation state of the transfection agent. Accordingly, certain methods according to the ... 12/21/06 - 20060287269 - Short interfering nucleic acid hybrids and methods thereof Disclosed herein are siHybrids used for gene silencing. An siHybrid is a short double-stranded molecule comprised of one strand of DNA and one strand of RNA, annealed together, with a 2-base overhang at each 3′ end. In addition to DNA and RNA, it may contain PNA or other nucleic acid ... 12/21/06 - 20060287268 - Splice-region antisense composition and method Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is a phosphorodiamidate-linked morpholino oligonucleotide ... 12/21/06 - 20060287267 - Rna interference mediated inhibition of respiratory syncytial virus (rsv) expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating sespiratory syncytial virus (RSV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression ... 12/21/06 - 20060287266 - Rna interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 12/21/06 - 20060287265 - Apoptosis-specific eif-5a and polynucleotides encoding same The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis. ... 12/21/06 - 20060287264 - Rnai modulation of the bcr-abl fusion gene and uses thereof The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides. ... 12/21/06 - 20060287263 - Methods and compositions for inducing antigen-specific immune responses Vaccine compositions comprising (a) an oligonucleotide, (b) and immune stimulating complex and (c) an antigen induce a strong interferon-gamma immune response. Both oligonucleotides containing immune stimulatory motifs and oligonucleotides lacking immune stimulatory motifs contribute to an interferon-gamma response when administered with an immune stimulating complex. ... 12/21/06 - 20060287262 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked ... 12/21/06 - 20060287261 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of ... 12/21/06 - 20060287260 - Oligonucleotides comprising a non-phosphate backbone linkage One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, ... 12/21/06 - 20060287259 - Compositions and methods for combined therapy of disease A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to ... 12/21/06 - 20060287258 - Treatment of menorrhagia, dysmenorrhoea or endometriosis A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor. ... 12/14/06 - 20060281704 - Regulation of endogenous gene expression in cells using zinc finger proteins The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. ... 12/14/06 - 20060281703 - Treatment of disease using an improved regulated expression system The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and ... 12/14/06 - 20060281702 - Combinatorial selection of phosphorothioate aptamers for rnases The present invention includes the selection and isolation of thioaptamers that target the ribonuclease domains of enzymes, e.g., HIV reverse transcriptase. ... 12/14/06 - 20060281701 - Antisense antiviral compounds and methods for treating a filovirus infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg ... 12/14/06 - 20060281700 - Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators where R3, B, Z, Q, p, q and R1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3. ... 12/14/06 - 20060281699 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid ... 12/14/06 - 20060281698 - Modulation of apolipoprotein (a) expression Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided. ... 12/14/06 - 20060281697 - Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they ... 12/14/06 - 20060281696 - Decoy-oligonucleotide-inhibition of cd40-expression The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 36 and their use as pharmaceutical agents. ... 12/07/06 - 20060276427 - Regulation of endogenous gene expression in cells using zinc finger proteins The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. ... 12/07/06 - 20060276426 - Human peroxisome proliferator activated receptor gamma (ppargamma) gene regulatory sequences and uses therefor This invention relates to the isolation and cloning of the promoter and other control regions of human PPARγ gene. It provides methods for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of the PPARγ gene. These agents interact ... 12/07/06 - 20060276425 - Antisense oligomers and methods for inducing immune tolerance and immunosuppression A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, ... 12/07/06 - 20060276424 - Compositions and methods for treatment of prostate and other cancers Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for ... 12/07/06 - 20060276423 - Survivin-directed rna interference-compositions and methods The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short ... 12/07/06 - 20060276422 - Rna interference mediated inhibition of b7-h1 gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating B7-H1 (also known as PD-L1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of B7-H1 gene ... 12/07/06 - 20060276421 - Staple type oligonucleotide and drug comprising the same Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing ... 12/07/06 - 20060276420 - Mesoderm and definitive endoderm cell populations The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. ... 11/30/06 - 20060270624 - Gapped 2' modified oligonucleotides Oligonucleotides and other macromolecules are provided that have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and sub-sequences of 2′-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H enzyme. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the ... 11/30/06 - 20060270623 - Rna interference mediated treatment of polyglutamine (polyq) repeat expansion diseases using short interfering nucleic acid (sina) The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of diseases and conditions associated with polyglutamine repeat (polyQ) allelic variants that respond to the modulation of gene expression and/or activity. The present invention also concerns compounds, compositions, and methods relating to diseases and conditions associated ... 11/30/06 - 20060270622 - Article of manufacture and method for disease treatment A method of treating a disease associated with a pathological cell population is disclosed. The method comprises increasing an association of complement with the pathological cell population in a subject in need of treatment, and decreasing a level and/or activity of a polypeptide in the pathological cell population, the polypeptide ... 11/30/06 - 20060270621 - Inhibition of hair growth with rnai targeting desmoglein 4 and nude mrnas Methods for inhibition of desmoglein 4 and nude protein mRNA using RNA interference are described, in particular methods for inhibition or hair growth or hair removal. Also described are nucleic acid constructs for RNAi-mediated inhibition of desmoglein 4 and nude protein mRNA and compositions including such constructs. ... 11/30/06 - 20060270620 - Method of enhancing therapeutic effect of nucleic acids The present invention is a method of eliciting an antitumor effect in vivo comprising the steps of identifying a species representative of a treatment subject, identifying at least one non-coding nucleic acid sequence, introducing the at least one nucleic acid to at least one tumor in the treatment subject and ... 11/30/06 - 20060270619 - Genes and polypeptides relating to human pancreatic cancers The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against ... 11/30/06 - 20060270618 - Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases The present invention relates to a novel pharmaceutical composition comprising interferon-γ or pirfenidone and a diagnostic array of candidate polynucleotides for the improved treatment of lung diseases, especially for all forms of interstitial lung diseases. This invention describes the combination of molecular diagnosis and clinical therapy as a novel medication ... 11/23/06 - 20060264396 - Composition for treatment of prevention of endometrial cancer and method of preventing or treating endometrial cancer using the composition Provided are a composition for the treatment or prevention of an endometrial cancer including a nuclear acid molecule inducing RNA interference against human syndecan-1 gene expression and a pharmaceutically acceptable carrier, and a method of treating or preventing an endometrial cancer including administering the composition to an individual. ... 11/23/06 - 20060264395 - Modulation of apolipoprotein c-iii expression Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided. ... 11/23/06 - 20060264394 - Livin-specific sirnas for the treatment of therapy-resistant tumors Provided is the use of siRNAs which are specific for the inhibitor of apoptosis protein (IAP) livin to sensitize tumor cells for apoptosis by down-regulating livin expression. ... 11/23/06 - 20060264393 - Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases The invention discloses a knockout mouse that is homozygous for a RUNX3 null allele, as a novel model for chronic inflammatory disease. The present invention provides methods for treating T cell-related inflammatory conditions by cell therapy, gene therapy or antisense for up regulating or down regulating RUNX3. The invention further ... 11/23/06 - 20060264392 - Modulators of angiogenesis The present invention relates to regulation of angiogenesis. More particularly, the present invention is directed to nucleic acids encoding “angiogenesis regulatory proteins and nucleic acids” which are involved in modulation of angiogenesis. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic ... 11/23/06 - 20060264391 - Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences The invention provides new methods of preventing and/or treating herpes virus infections, particularly reducing infection, one or more symptoms and recurrence of one or more symptoms of herpes simplex virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being ... 11/16/06 - 20060258611 - Inhibition of sars-associated coronavirus (scov) infection and replication by rna interference The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the ... 11/16/06 - 20060258610 - Modulation of stat 6 expression for the treatment of airway hyperresponsiveness Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or ... 11/16/06 - 20060258609 - Method for inhibition of lipogenesis by regulating prp19 expression The downregulation of PRP 19 (precursor RNA processing 19) protein expression results in effectively reducing the expression of SCD1 (stearyl CoA desaturase-1), the key lipogenic enzyme, and its down-stream triacylglycerol synthesis enzymes, DGAT-1 (diacyglycerol acyltransferase-1) and GPAT (glycerol-phosphate acyltransferase), as well as the intracellular content of neutral lipids, the major ... 11/16/06 - 20060258608 - Rnai modulation of rsv and therapeutic uses thereof The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based ... 11/16/06 - 20060258607 - Ghrelin binding nucleic acids The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight ... 11/16/06 - 20060258606 - Transforming growth factor-beta response element decoys and methods Products and methods for treating fibrosis, liver cirrhosis and cancer, and for altering or modulating the expression of genes regulated by transforming growth factor—beta (TGF-β) are provided. Nucleic acid molecules comprising TGF-response elements have a high affinity for transcription factors modulated by TGF-β. In one embodiment, nucleic acid molecules comprising ... 11/16/06 - 20060258605 - Nucleolin-mediated cancer diagnostics and therapy The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules ... 11/16/06 - 20060258604 - Compositions and methods for the treatment of inflammatory bowel disease utilizing nf-kappab decoy polynucleotides Provided herein is a method of treating or preventing inflammatory bowel disease (IBD) in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an NF-κB decoy polynucleotide. ... 11/16/06 - 20060258603 - Transposon-based targeting system The present invention relates to a targeting system comprising, preferably as distinct components (a) a transposon which is devoid of polynucleotide encoding a functional transposase comprising (aa) a polynucleotide of interest and; (ab) a DNA sequence specifically recognized by a DNA binding domain; and (ba) a fusion protein comprising (i) ... 11/16/06 - 20060258602 - Site-specific gene conversion promoter and gene therapeutic It is intended to provide a preparation whereby an oligonucleotide is efficiently transferred into a cell and the localization thereof in nucleus is promoted, a preparation for facilitating the conversion of the base sequence of a target genomic gene, and a preparation for gene therapy. Namely, a preparation for facilitating ... 11/16/06 - 20060258601 - Formulation for inwardly transferring nucleic acids into eucaryotic cells The present invention relates to a pharmaceutical formulation for the funnelling of nucleic acids into eukaryotic cells, characterised in that the formulation has a pH-value within the range of pH 6.0 to pH 7.4, and/or an anion concentration within the range from 5 to 100 mmol/l and/or provides nonsteroidal anti-inflammatory ... 11/09/06 - 20060252724 - Method and composition for modulating bone growth Methods and compositions are provided for the treatment of defects and disease involving osteoporosis or osteopenic conditions. The methods comprise applying to the site of osteoporotic or osteopenic conditions a composition comprising a BMP-3 inhibitor or antagonist. The invention further provides methods and compositions for modulating or regulating the formation ... 11/09/06 - 20060252723 - Combined therapy utilizing reduction of dna methyltransferase expression and/or activity and interferon The invention provides methods for the treatment of cancer comprising a reduction of DNA methyltransferase expression and/or activity and treatment and/or induction of interferon. The invention overcomes resistance of cancer cells to interferon ... 11/09/06 - 20060252722 - Oligomeric compounds and compositions for use in modulation of pri-mirnas Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided ... 11/09/06 - 20060252721 - Potent lna oligonucleotides for the inhibition of hif-1a expression The present disclosure relates to an LNA oligonucleotide consisting of a sequence selected from the group consisting of 5′-(Tx)GxGxcsasasgscsastscscsTxGxT-3′ and 5′-(Gx)TxTxascstsgscscststscsTxTxA-3′, wherein capital letters designate a beta-D-oxy-LNA nucleotide analogue, small letters designate a 2-deoxynucleotide, underline designates either a beta-D-oxy-LNA nucleotide analogue or a 2-deoxynucleotide, subscript “s” designates a phosphorothioate link ... 11/09/06 - 20060252720 - Modulation of hif1 beta expression Compounds, compositions and methods are provided for modulating the expression of HIF1-beta. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1-beta. Methods of using these compounds for modulation of HIF1-beta expression and for diagnosis and treatment of diseases and conditions associated with expression of HIF1-beta are provided. ... 11/09/06 - 20060252719 - Compositions and methods to modulate h. influenzae pathogenesis The present invention discloses novel signaling pathways controlling the pathogenesis of the human respiratory bacterium, Haemophilus influenzae. The lipooligosaccharide-phosphorylycholine (LOS-PC) cell surface epitope of H. influenzae enhances pathogenesis but also increases bacterial susceptibility to innate and adaptive immunity and the administration of therapeutic compounds. Modulation of the LOS-PC epitope may ... 11/09/06 - 20060252718 - Sphingolipids polyalkylamine conjugates for use in transfection The present invention concerns the use of a sphingoid-polyalkylamine conjugate comprising a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine chains as a capturing agent of nucleic acid molecules. The present invention also provides the use of the sphingoid polyalkylamine conjugate for the preparation of a pharmaceutical ... 11/09/06 - 20060252717 - Sphingoid polyalkylamine conjugates for vaccination The present invention concerns the use of a sphingoid-polyalkylamine conjugate as a capturing agent of biologically active molecules, such as antigens. In a particular embodiment, the spinogid-polyalkylamines are used for the preparation of pharmaceutical composition for modulating the immune response of a subject. Other aspects of the invention concern methods ... 11/09/06 - 20060252716 - Method for reversing the immunosuppressive effects of the melanoma inhibitory activity mia A method for stimulating immune cells and/or the immune system, and/or reducing invasion and/or metastasis of tumor cells by inhibiting expression and/or functional activity of “Melanoma Inhibitory Activity” MIA. ... 11/02/06 - 20060247202 - Recombinant constructs and their use in reducing gene expression Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target ... 11/02/06 - 20060247201 - Myeloid colony stimulating factor and uses thereof The identification of the HYAL1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in ... 11/02/06 - 20060247200 - Methods and uses of leukotriene b4 hydroxylases to treat diseases Methods and uses are described for treating or preventing diseases of humans or non-human animals by reducing the amount of active leukotriene B4 (LTB4) in those in need of such treatment using LTB4 hydroxylases. In certain embodiments, LTB4 hydroxylase is administered in combination with nicotinamide adenine dinucleotide phosphate and/or an ... 11/02/06 - 20060247199 - Methods and products for manipulating uncoupling protein expression The invention is based in part on the discovery that uncoupling proteins (UCPs) are expressed in the plasma membrane of rapidly dividing cells but not of growth arrested, chemotherapy resistant cells. It has also been found according to the invention that UCP is expressed in the lysosomal membrane under certain ... 11/02/06 - 20060247198 - Tgf-beta type receptor cdnas encoded products and uses therefor DNA encoding TGF-β type III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor, TGF-β type II receptor and uses therefor. ... 11/02/06 - 20060247197 - Method for down-regulating gene expression in fungi The present invention concerns methods for controlling fungus infestation via dsRNA mediated gene silencing, whereby the intact fungus cell(s) are contacted with a double-stranded RNA from outside the fungal cell(s) and whereby the double-stranded RNA is taken up by the intact fungal cell(s). In one particular embodiment, the methods of ... 11/02/06 - 20060247196 - Yeast genes that affect viral replication An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1i gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 ... 11/02/06 - 20060247195 - Method of altering cell properties by administering rna The invention relates to the alteration of cell properties using RNA molecules. In particular, it relates to the alteration of the ability of cells to mobilise, migrate, integrate, proliferate and/or differentiate. For example, it relates to the induction of differentiation of stem cells, including the acquisition of the ability to ... 11/02/06 - 20060247194 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating beta-secretase (BACE), amyloid precurson protein (APP), PIN-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity ... 11/02/06 - 20060247193 - Regulation of gene expression by dna interference The present invention provides products and methods for modulating expression of a target gene in a cell. One such method includes introducing into the cell a polynucleotide that forms a duplex region with an mRNA transcribed from said target gene, where the duplex region comprises a mammalian miRNA target region. ... 11/02/06 - 20060247192 - Control of apoptosis A method for suppressing the expression of a selected apoptosis-related gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site at or associated with the selected gene which site is present in a genome and ... 11/02/06 - 20060247191 - Chimeric cytoplasmic signalling molecules Nucleic acids are described which code for chimeric cytoplasmic signalling molecules containing at least one cytoplasmic signalling sequence derived from CD134 or ICOS. The nucleic acids may be expressed in cells to produce chimeric receptors and other proteins which are able to regulate cell activation processes. Such regulated cells are ... 11/02/06 - 20060247190 - Compositions and methods for treating human papillomavirus mediated disease The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to the ... 10/26/06 - 20060241076 - Modified oligoribonucleotide analogs with enhanced immunostimulatory activity The invention provides immunostimulatory compositions and methods for their use. In particular, the immunostimulatory compositions of the invention include RNA-like polymers that incorporate an immunostimulatory sequence motif and at least one chemical modification to confer improved stability against nuclease degradation and improved activity. Specific modifications involving phosphate linkages, nucleotide analogs, ... 10/26/06 - 20060241075 - Rna interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating Desmoglein (e.g, DSG1, DSG2, DSG3, and/or DSG4) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ... 10/26/06 - 20060241074 - Methods for treatment of pain The present invention relates to a method for the treatment or prevention of pain by administering to an animal an agent that decreases the activity of the complement cascade. ... 10/26/06 - 20060241073 - Means and methods for counteracting fatty acid accumulation The invention provides a method for, at least, in part, counteracting a disease involving accumulation of a fatty acid, the method comprising administering a compound which is capable of inducing and/or upregulating omega-oxidation of the fatty acid, or whose metabolite is capable of inducing and/or upregulating omega-oxidation of the fatty ... 10/26/06 - 20060241072 - Oligomeric compounds for use in gene modulation The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification. The present invention also provides methods for modulating gene expression using the modified oligomeric ... 10/26/06 - 20060241071 - Functional synthetic molecules and macromolecules for gene delivery The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of ... 10/26/06 - 20060241070 - Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treament of cancer The present invention provides antisense oligonucleotides directed to a mammalian ribonucleotide reductase R2 gene and combinations of the antisense oligonucleotides with one or more chemotherapeutic agents for use in the treatment of cancer. ... 10/26/06 - 20060241069 - Treatment of hyperproliferative disease A short interfering RNA (siRNA) duplex that includes complementary sense and anti-sense sequences corresponding to at least part of the A3 adenosine receptor (A3AR) mRNA sequence, a double-stranded RNA (dsRNA) construct that can be converted within a cell into a siRNA duplex and a transcript system that can induce transcription ... 10/26/06 - 20060241068 - Novel actin-associated cytosekeltone protein lacs The present invention provides the novel actin-related cytoskeletal protein LACS and genes encoding the protein. ... 10/26/06 - 20060241067 - Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival The invention relates to methods for detecting and inhibiting angiogenesis, cell migration, cell adhesion, and/or cell survival in endothelial and non-endothelial cells as well as in normal and tumor cells. The invention further relates to methods for screening test compounds for their ability to inhibit angiogenesis, cell migration, cell adhesion, ... 10/26/06 - 20060241066 - Decoy composition for treating and preventing inflammatory disease It is intended to efficiently treat an inflammatory disease without causing side effects. This object can be achieved by providing a medicinal composition for treating and preventing an inflammatory disease and disorders, and disorders caused by the disease and disorders which contains at least one decoy of NF-κB or an ... 10/19/06 - 20060234973 - Transcription factor rna interference reagents and methods of use thereof The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering ... 10/19/06 - 20060234972 - Compositions and their uses directed to thymus and activation-regulated chemokine (tarc) Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression ... 10/19/06 - 20060234971 - Calpains as targets for inhibition of prion propagation The present invention relates to methods for the inhibition of disease-associated prion formation and propagation. Such methods are based on inhibition of PrPSc cleavage, which prevents PrPSc accumulation and results in reduced prion titers. More particularly, the present invention relates to endoproteolytic cleavage of PrPSc by calpain, a calcium (Ca2+)-activated ... 10/19/06 - 20060234970 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of ... 10/19/06 - 20060234969 - Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia Compositions and methods for inhibiting inflammation of vessel wall and/or formation of neointimal hyperplasia by gene therapy using a soluble Flt-1 (sFlt-1) gene, are provided. VEGF has an essential role in the development of neointimal hyperplasia by causing inflammation. sFlt-1 gene transfer to the site of vascular injury blocks Flt-1-mediated ... 10/19/06 - 20060234968 - Inhibition of the cd95 ligand/receptor system for the treatment of neurological disorders and injuries The present invention relates to the use of inhibitors of the CD95 ligand/receptor system for the manufacture of a medicament for the treatment of neurological disorders or injuries in a mammal, particularly for the treatment of spinal cord injury, more particularly for the treatment of paraplegia. ... 10/19/06 - 20060234967 - Human protooncogene and protein encoded therein The present invention relates to a novel proto-oncogene HPP1 (Human proto-oncogene 1), which is non-homologous to existing oncogenes and the protein encoded by the said oncogene. This novel proto-oncogene can be advantageously used in diagnosing of various cancers; in construction of transformed animals; and in anti-sense gene therapy. The present ... 10/19/06 - 20060234966 - Method for expressing inducible rna [in cells, nucleic acid molecules therefor and cells transformed by said molecules A method of expressing RNAi in cells including introducing into cells a molecule of nucleic acid including the sequence sense and antisense of RNAi placed under the control of a promoter of single transcription, which sense and antisense sequences are separated by a sequence of DNA including a sequence for ... 10/19/06 - 20060234965 - Novel full-length genomic rna of japanese encephalitis virus, infectious jev cdna therefrom, and use thereof The present invention relates to a novel genomic RNA of Japanese encephalitis virus (JEV) and an infectious JEV cDNA therefrom. Particularly, the present invention relates to a full-length genomic RNA of JEV represented by SEQ. ID. No 15 and an infectious JEV cDNA therefrom. JEV genomic RNA and infectious JEV ... 10/19/06 - 20060234964 - Inducible plasmid vector encoding tgf-beta and use thereof The present invention provides alternatives to traditional drug and surgical treatments for IBD. In particular, the present invention provides compositions and methods for the treatment of autoimmune diseases such as IBD in humans using TGF-β therapy. The compositions of the present invention provide vectors containing TGF-β under the control of ... 10/12/06 - 20060229273 - High affinity oligonucleotide ligands to growth factors Methods are described for the identification and preparation of high-affinity nucleic acid ligands to TGFβ, PDGF and hKGF. Included in the invention are specific RNA and ssDNA ligands to TGFβ1 and PDGF identified by the SELEX method. Also included in the invention are specific RNA ligands to hKGF identified by ... 10/12/06 - 20060229272 - Human g-protein coupled receptor, hgprbmy11, and variants thereof The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing these polypeptides. The invention further relates to diagnostic ... 10/12/06 - 20060229271 - Methods for treating infectious disease exacerbated asthma The invention relates to methods of treating infectious disease exacerbated asthma. In particular, the methods are useful for treating viral exacerbated asthma using CpG oligonucleotides. ... 10/12/06 - 20060229270 - Methods of treating proteinuria by reducing double-stranded dna antibodies The invention provides methods of treating proteinuria in an individual such as human by administering an effective amount of an agent that reduces the level of anti-dsDNA antibodies (such as a dsDNA epitope as in the form of an epitope-presenting carrier or an epitope-presenting valency platform molecule like LJP 394) ... 10/12/06 - 20060229269 - Emergence of a r-type ca²+ channel (cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage The invention relates to methods and products for treatment of a neurological defect such as a subarachnoid hemorrhage or cerebral vasospasm. Specifically, R-type voltage-gated calcium channel inhibitors and related compositions and kits are described. ... 10/12/06 - 20060229268 - Small interference rna (sirna) molecules for modulating superoxide dismutase (sod) The invention pertains to using double stranded ribonucleic acid molecules such as small interfering RNA (siRNA) molecules to target an SOD gene to interfere with gene expression and SOD protein production. Method are disclosed for inhibiting expression of a target protein in a subject with a neurological disorder by introducing ... 10/12/06 - 20060229267 - Methods and compositions for the inhibition of gene expression The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers. ... 10/12/06 - 20060229266 - Silencing of tgf-beta receptor type ii expression by sirna The present application is directed to siRNA-based silencing of the type II receptor of TGFβ. siRNAs that target this receptor abrogate the receptor protein and transcript, TGFβ-mediated processes such as fibronectin assembly and cell migration also are inhibited and the molecules of the invention are efficacious in reducing the inflammatory ... 10/05/06 - 20060223779 - Method of screening for inhibitors of human fatty acid-coa ligase 4 The present invention provides a method of screening for potential cancer chemotherapeutic and chemopreventive agents which act by modulating the activity of the Fatty Acid-CoA Ligase 4 (FACL4) gene product in humans. This invention also provides methods of administering such agents to treat cancer by inhibiting the activity of the ... 10/05/06 - 20060223778 - Circular nucleic acid vectors, and methods for making and using the same Circular nucleic acid vectors that provide for persistently high levels of protein expression are provided. The circular vectors of the subject invention are characterized by being devoid of expression-silencing bacterial sequences, where in many embodiments the subject vectors include a unidirectional site-specific recombination product hybrid sequence in addition to an ... 10/05/06 - 20060223777 - Highly functional short hairpin rna The present invention provides improved hairpin and fractured hairpin constructs for use in gene silencing through the RNA interference pathway. An exemplary short hairpin polynucleotide for use in gene silencing can include a polynucleotide having from about 42 nucleotides to about 106 nucleotides configured for being processed by Dicer. The ... 10/05/06 - 20060223776 - Microgel particles for the delivery of bioactive materials Novel microgels, microparticles and related polymeric materials capable of delivering bioactive materials to cells for use as vaccines or therapeutic agents. The materials are made using a crosslinker molecule that contains a linkage cleavable under mild acidic conditions. The crosslinker molecule is exemplified by a bisacryloyl acetal crosslinker. The new ... 10/05/06 - 20060223775 - Nucleotide sequence for treating cancer and infection A nucleotide sequence comprising the nucleotide sequence of a virus belonging to the group of autonomous parvoviruses, and at least one effector nucleotide sequence which encodes an effector polypeptide capable of effecting the destruction or the normalization of cancer cells or cells infected by virus, bacteria, or intra-cellular infectious parasites. ... 10/05/06 - 20060223774 - Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof The present invention relates to the discovery, identification and characterization of toxic agents which are lethal to pathogens and methods for targeting such toxic agents to a pathogen or pathogen infected cells in order to treat and/or eradicate the infection. In particular, the present invention relates to toxic agents which ... 10/05/06 - 20060223773 - Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma. ... 10/05/06 - 20060223772 - Vectors comprising guinea pig cmv regulatory elements The invention comprises novel polynucleotides, and related vectors, host cells, methods, and compositions, containing transcriptional enhancers providing very high levels of expression of operably-linked expressible nucleic acid sequences in eukaryotic cells. Advantageously the enhancers may be used in combination with their naturally-associated promoters and/or other genetic elements that increase transcription. ... 10/05/06 - 20060223771 - Nuclear factor kappab inducing factor The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are ... 10/05/06 - 20060223770 - Irna agents targeting vegf The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified. ... 10/05/06 - 20060223769 - Vaccines using nucleic acid-lipid complexes This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated ... 10/05/06 - 20060223768 - Regulation of gene expression The present invention relates to a method of regulating apoptosis. The method comprises the step of introducing into a cell an RNA construct comprising a nucleotide sequence which is homologous to mRNA within said cell. The mRNA within the cell includes genetic information of a gene element involved in the ... 10/05/06 - 20060223767 - Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene therapy Disclosed is a vector for gene therapy, by which the blood level of a desired protein can be monitored at high sensitivity when a gene therapy is conducted, wherein the label peptide does not have a physiological activity and has no immunogenicity in many mammals. The vector for gene therapy ... 09/28/06 - 20060217342 - Novel oncogene, recombinant protein derived therefrom, and uses thereof The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a ... 09/28/06 - 20060217341 - Dna vaccine formulations This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products. ... 09/28/06 - 20060217340 - Methods and products for treating hypertension by modulation of trpc3 channel activity The invention relates to methods and products for treatment of hypertension, high blood pressure and vasospasm. Specifically, TRPC3 channel inhibitors and related compositions and kits are described. ... 09/28/06 - 20060217339 - Antisense oligonucleotide modulation of stat3 expression Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and ... 09/28/06 - 20060217338 - Influenza nucleic acids, polypeptides, and uses thereof Codon-optimized nucleic acids encoding influenza polypeptides and uses of the nucleic acids and polypeptides for inducing immune responses are provided herein. ... 09/28/06 - 20060217337 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217336 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217335 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217334 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina) The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA ... 09/28/06 - 20060217333 - Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function The invention provides methods treating lupus nephritis based in individuals with significantly impaired renal function, and methods of selecting individuals for treatment based on significantly impaired renal function. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such ... 09/28/06 - 20060217332 - Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating VEGF and/or VEGFR gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of VEGF and/or VEGFR gene ... 09/28/06 - 20060217331 - Chemically modified double stranded nucleic acid molecules that mediate rna interference This invention relates to compounds, compositions, and methods useful for modulating gene expression using chemically modified double stranded nucleic acid molecules. In particular, the instant invention features double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA ... 09/28/06 - 20060217330 - Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas This invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals. ... 09/28/06 - 20060217329 - Therapeutic uses of inhibitors of rtp801 The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein. ... 09/28/06 - 20060217328 - Synergisitic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the ... 09/28/06 - 20060217327 - Sirna expression system The authors describe an expression system for the correct, stable and effective expression in mammalian cells of a siRNA comprising: a) a polymerase H RNA-dependent promoter derived from the U1 RNA gene; downstream from the sequence b) suitable restriction sites for the cloning of the sequence transcribing the pre-siRNA; downstream ... 09/28/06 - 20060217326 - Group of nucleic acid fragments for prevention of hiv infection or aids and the usage thereof The invention provides a group of nucleic acid fragments, shown in the sequence listing, for prevention of HIV infection or AIDS and the usage thereof. In the invention, a series of RNA fragments, which are highly homogenous to all the published HIV gene sequences, were obtained by homology compare. The ... 09/28/06 - 20060217325 - Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cells The present invention provides compositions comprising the 15-lipoxygenase-1 (15-LO-1) or 15-lipoxyngenase-2 (15-LO-2) gene such that 15-LO-1 or 15-LO-2 protein expression is replaced or replenished in the ocular surface epithelium of post-menopausal women suffering from dry eye. Thus, methods for treatment of dry eye in postmenopausal women are further provided. ... 09/21/06 - 20060211647 - Nonviral vectors for delivering polynucleotides Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided. ... 09/21/06 - 20060211646 - Formulations with anti-tumour action The use of defibrotide as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. ... 09/21/06 - 20060211645 - Modulation of neurodegenerative diseases Methods and compositions are disclosed for selectively interfering with protein synthesis in a central nervous system, meningial, or muscle cell by administrating a pharmacological agent. In particular, methods and compositions that interfere with SOD-1 protein synthesis are disclosed. ... 09/21/06 - 20060211644 - Immunostimulatory oligonucleotides The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides. ... 09/21/06 - 20060211643 - Polycations capable of forming complexes with nucleic acids A polycation capable of forming a complex with a nucleic acid for carriage thereof. The polycation comprising at least one cyclic compound having a cavity. A polymer backbone is threaded into the cavity of the cyclic compound. A pair of bulky moieties cap the terminals of the polymer backbone to ... 09/21/06 - 20060211642 - Rna inteference mediated inhibition of hepatitis c virus (hvc) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating Hepatitis C Virus (HCV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HCV gene expression ... 09/21/06 - 20060211641 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of ... 09/21/06 - 20060211640 - Antisense modulation of farnesoid x receptor expression Antisense compounds, compositions, and methods are provided for modulating the expression of Farnesoid X Receptor (FXR). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding FXR. Methods of using these compounds for modulation of FXR expression and for treatment of diseases associated with expression of FXR ... 09/21/06 - 20060211639 - Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions ... 09/21/06 - 20060211638 - Exon 1 ss of pdgf alpha gene and utilization thereof By using an antisense nucleotide, a ribozyme, a maxizyme, or an RNAi constructed based on the nucleotide sequence of exon 1 beta of the PDGF receptor alpha gene, which is expressed in specific cancer cells, or a polypeptide containing a portion thereof, translation of an mRNA transcribed from exon 1 ... 09/21/06 - 20060211637 - Methods of down regulating target gene expression in vivo by introduction of interfering rna Methods and compositions are provided for down regulation of target gene expression in vivo by RNA interference. The methods are useful for target discovery and validation of gene-based drug development, and for treatment of human diseases. ... 09/14/06 - 20060205689 - Bivm (basic, immunoglobulin-like variable motif-containing) gene, transcriptional products, and uses thereof The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected ... 09/14/06 - 20060205688 - Method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase The present invention relates generally to a method of modulating endothelial cell functional characteristics and to agents useful for same. More particularly, the present invention relates to a method of modulating vascular endothelial cell pro-inflammatory and angiogenic phenotypes by modulating the functional levels of intracellular sphingosine kinase. The method of ... 09/07/06 - 20060199782 - Compositions and methods for therapeutic use n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group ... 09/07/06 - 20060199781 - Assays based on btf3 activity This invention pertains to the discovery that BTF3 plays a critical, negative-regulatory role in programmed cell death (PCD) in C. elegans and other species. Overexpression of BTF3 leads to decreased programmed cell death, while inactivation of BTF3 leads to increased programmed cell death. Methods of modulating (upregulating or downregulating) programmed ... 09/07/06 - 20060199780 - Methods for modulating t cell survival by modulating bcl-xl protein level Methods for protecting a T cell from cell death are described. The methods involve contacting the T cell with an agent which augments the bcl-XL protein level in the T cell such that it is protected from cell death. The invention further pertains to methods for increasing the susceptibility of ... 09/07/06 - 20060199779 - Compositions and methods for short interfering nucleic acid inhibition of nav1.8 The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method ... 09/07/06 - 20060199778 - Methods and products related to non-viral transfection The invention relates to compositions and methods for the non-viral delivery of nucleic acid molecules and/or organelles to cells in vitro and in vivo. The non-viral delivery complexes provided by the invention comprise cholera toxin B subunit or functional equivalents thereof and preferably cyclodextrin. ... 09/07/06 - 20060199777 - Novel technology of intracellular delivery of dna oligonucleotides to improve drug activity The present invention relates to methods of intracellular delivery of oligonucleotides. More particularly, the present invention relates to the use of the delivery system to deliver G-quartet oligonucleotides as a cancer therapy or an anti-viral therapy. ... 08/31/06 - 20060194754 - Methods for delivering nucleic acid molecules into cells and assessment thereof Methods for delivering nucleic acid molecules into cells and methods for measuring nucleic acid delivery into cells and the expression of the nucleic acids are provided. The methods are designed for introduction of large nucleic acid molecules, including artificial chromosomes, into cells, and are practiced in vitro and in vivo. ... 08/31/06 - 20060194753 - Agent for treating leishmania infections Use of a combination of DNA expression constructs for the production of a remedy for the immunization against infections with leishmaniasis, as well as a corresponding vaccine. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). As stated in 37 C.F.R. §1.72(b): A brief abstract ... 08/31/06 - 20060194752 - Treatment for renal disease Methods for treating or preventing renal disease or inducing passive immunity against renal disease by administering polynucleotides encoding MCP-1 or both MCP-1 and RANTES are provided. Compositions containing polynucleotides encoding MCP-1 or both MCP-1 and RANTES are also provided. ... 08/31/06 - 20060194751 - Streptococcus pyogenes antigens The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefor ... 08/31/06 - 20060194750 - Methods and materials for modulating trpc4 The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of TRPC4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TRPC4. ... 08/24/06 - 20060189564 - Methods and sequences to suppress pro-inflamatory cytokine actions locally to treat pain Disclosed herein are methods and sequences used to treat pain. Specifically, the methods and sequences include locally administering nucleic acid molecules that suppress the expression of amino acid sequences that encode for pro-inflammatory cytokines and their receptors to treat acute or neuropathic pain associated with sciatica. ... 08/24/06 - 20060189563 - Detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides. ... 08/24/06 - 20060189562 - In vitro-differentiated retinal ganglion cells and method for producing same In vitro-differentiated retinal ganglion cells can be produced by exposing a mammalian retinal ganglion cell line to a protein kinase inhibitor. The differentiated retinal ganglion cells can be used to identify agents that protect retinal ganglion cells in vivo or in vitro from cell injury (including cell death) and agents ... 08/24/06 - 20060189561 - Rnai expression constructs with liver-specific enhancer/promoter The present invention provides compositions and methods suitable for RNAi specifically in the liver so as to treat diseases or disorders. ... 08/24/06 - 20060189560 - Molecular method to augment rna mediated gene silencing The invention provides for a novel method of augmenting gene silencing via RNA interference (RNAi). Under the invention, RNAi technology is combined with the action of a variant nuclear factor to potently inhibit gene expression. In one embodiment of the invention, the nuclear factor is a variant of a double-stranded ... 08/24/06 - 20060189559 - Method and system for treating hepatitis c A method and system for treating Hepatitis C includes using an implantable pump and an outlet catheter. A proximal end of the outlet catheter is fluidly connected to an outlet port of the pump. A distal end of the outlet catheter is sized to deliver medication from the pump to ... 08/24/06 - 20060189558 - Delivery of substances to cells Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells. ... 08/24/06 - 20060189557 - Regulation of oncogenes by micrornas Naturally occurring miRNAs that regulate human oncogenes and methods of use therof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA ... 08/24/06 - 20060189556 - Dna cancer vaccines A plurality of DNA cancer vaccines and their uses in treating cancer are disclosed. Genes encoding Mycobacterium bovis bacillus Calmette-Guérin (M. bovis BCG) recombinant antigens and genes encoding interlukin-12 heterodimer were respectively cloned into eukaryotic expression vectors to express the encoded recombinant proteins in mammalian cells in vivo whereby specific ... 08/24/06 - 20060189555 - Pyrroles substituted by oligonucleotides The invention relates to novel pyrrole derivatives of the formula (I) which make it possible to immobilize and address oligonucleotides by electropolymerization. Said invention also relates to thus produced electroactive polymers and to methods for using them for detecting, identifying and dosing analytes in a sampe. (I) wherein R1 is ... 08/24/06 - 20060189554 - Nanoparticle-based vaccine delivery system containing adjuvant A vaccine delivery system comprising adjuvant and nanoparticles comprising an immunogenic agent is provided. A method of immunizing an animal comprising administering a nanoparticle-based vaccine delivery system is also provided. ... 08/24/06 - 20060189553 - Nucleic acid injected into hapatic vein lumen and delivered to primate liver Processes are described for obtaining high levels of gene expression in primates after injection of nucleic acid to the liver via the lumen of the hepatic vein. The described process results in high level of gene expression with transient increases in liver enzymes. ... 08/17/06 - 20060183705 - Hepatitis c virus codon optimized non-structural ns3/4a fusion gene Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions ... 08/17/06 - 20060183704 - Method to inhibit cell growth using oligonucleotides Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising pTT or a composition comprising one or more oligonucleotides which share at least 50% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment ... 08/17/06 - 20060183703 - Circular expression construct for gene therapeutic applications Method for producing a circular minimalist expression construct closed in an annular manner, from a double-strand DNA, an expression construct produced according to said method, and the use of the same in gene therapy and vaccination. The abstract of the disclosure is submitted herewith as required by 37 C.F.R. §1.72(b). ... 08/17/06 - 20060183702 - Aptamers to von willebrand factor and their use as thrombotic disease therapeutics The invention relates generally to the field of nucleic acids and more particularly to aptamers capable of binding to von Willebrand Factor useful as therapeutics in and diagnostics of thrombotic diseases and/or other diseases or disorders in which von Willebrand Factor mediated platelet aggregation has been implicated. The invention further ... 08/17/06 - 20060183701 - Methods and compositions for determining non-specific cytotoxicity of a transfection agent Methods and compositions for determining cytotoxicity of a transfection agent are provided. In one aspect, a cell is contacted with a transfection agent. Following contact, a cytotoxic marker profile of the cell is evaluated to determine whether the transfection agent has mediated a cytotoxic response in the cell. Also provided ... 08/17/06 - 20060183700 - Cgrp binding nucleic acids The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide. ... 08/10/06 - 20060178337 - Method for diagnosing aplasia of corpus callosum Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial ... 08/10/06 - 20060178336 - Oral administration of therapeutic agent coupled to transporting agent induces tolerance The present invention is directed toward a method for the induction of tolerance to a foreign transgene or a self-antigen in an animal host by administration of a composition to an animal host via a natural gastrointestinal pathway. Additionally, the present method can eliminate a pre-existing immune response in an ... 08/10/06 - 20060178335 - Methods and means for obtaining modified phenotypes Methods and means are provided for reducing the phenotypic expression of a nucleic acid of interest in eucaryotic cells, particularly in plant cells, by introducing chimeric genes encoding sense and antisense RNA molecules directed towards the target nucleic acid, which are capable of forming a double stranded RNA region by ... 08/10/06 - 20060178334 - Double-stranded and single-stranded rna molecules with 5 ' triphosphates and their use for inducing interferon Double-stranded and single-stranded RNA molecules, and their use in methods for inducing interferon are provided. The interferon induction provides anti-viral and other medically useful effects, such as anti-cancer effects. Also provided are methods for reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in ... 08/10/06 - 20060178333 - Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the ... 08/10/06 - 20060178332 - Regulation of ccn2 by ccn3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases The present invention discloses a role of CCN3 in diseases associated with the overexpression of CCN2, which include but are not limited to kidney disease, fibrosis, and cancer. The full length CCN3 protein or fragments thereof or isoforms (or combinations) of CCN3 are involved in these diseases. The isolated and ... 08/10/06 - 20060178331 - Antisense oligonucleotides targeting folate receptor alpha, and the use thereof The invention relates to treatment of cancers and cancerous cells which over-express α folate receptor (FRα) compared to the normal cells of the same tissue. The invention is directed to antisense oligonucleotides which are complimentary to the coding region of FRα, as well as the pharmaceutical compositions made thereof, and ... 08/10/06 - 20060178330 - Use of antisense oligonucleotides or sirna to suppress expression of eif-5a1 The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The ... 08/10/06 - 20060178329 - Rnai probes targeting cancer-related proteins RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, ... 08/10/06 - 20060178328 - Devices, systems and methods for improving memory and/or cognitive function through brain delivery of sirna The present invention relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems and methods for direct delivery of the compositions ... 08/10/06 - 20060178327 - Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering rna precursors enabling the formation and function of small interfering rna in vivo and in vitro The use of specially selected sequences from the target gene into designing double stranded or other forms of RNA (siRNA precursors or siRNAp) that enables small interfering RNA (siRNA) from this new invention is delivered for inhibition of cellular gene expression. Diseases may be prevented and treated by this process, ... 08/10/06 - 20060178326 - Ribozyme therapy for the treatment of proliferative skin and eye diseases As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase. ... 08/10/06 - 20060178325 - Modulation of growth hormone receptor expression and insulin-like growth factor expression Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of ... 08/10/06 - 20060178324 - Lipophilic derivatives of double-stranded ribonucleic acid The present invention relates to a double-stranded ribonucleic acid (dsRNA) having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA. The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at ... 08/10/06 - 20060178323 - Methods for the treatment of chronic pain and compositions therefor The invention discloses MMP7 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory effect on MMP7 enzyme activity and/or MMP7 gene expression. The invention ... 08/03/06 - 20060172966 - Immunostimulatory g, u-containing oligoribonucleotides Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening ... 08/03/06 - 20060172965 - Rnai-mediated inhibition of ocular targets RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by ... 08/03/06 - 20060172964 - Methods for reducing amyloid beta levels The present invention relates to the treatment and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for reducing production of β amyloid by reducing or preventing the binding of amyloid precursor protein (APP) to an X11 adaptor protein. Also provided are methods for ... 08/03/06 - 20060172963 - Rnai-mediated inhibition of ocular hypertension targets RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by ... 08/03/06 - 20060172962 - Modification of myd88 splicing using modified oligonucleotides Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided. ... 08/03/06 - 20060172961 - Rnai inhibition of serum amyloid a for treatment of glaucoma RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression. ... 08/03/06 - 20060172960 - Therapy and diagnosis of conditions related to telomere length and/or telomerase activity Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric ... 08/03/06 - 20060172959 - Selected rna motifs to include cell death and/or apoptosis The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of ... 08/03/06 - 20060172958 - Phospholipid scramblase 3 Phospholipid scramblase 3 (PLS3) is a newly recognized member of a family of proteins responsible for phospholipid translocation between two lipid compartments. A novel isoform of PLS3 is identified and characterized herein. The function of PLS3 in mitochondria was disrupted, yielding an inactive mutant PLS3(F258V). Cells transfected with PLS3(F258V) exhibited ... 08/03/06 - 20060172957 - Antisense modulation of integrin beta 4 binding protein expression Antisense compounds, compositions and methods are provided for modulating the expression of Integrin beta 4 binding protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Integrin beta 4 binding protein. Methods of using these compounds for modulation of Integrin beta 4 binding protein expression and ... 07/27/06 - 20060166924 - Gene therapeutics Gene therapeutics to be used in treating diseases showing sensitivity to gene therapy, characterized by containing as the active ingredient an efficacious amount of a functional substance which has a function of having an affinity for a virus containing a gene usable in the gene therapy and another function of ... 07/27/06 - 20060166923 - Immune stimulating composition comprising bacterial chromosomal dna fragments having methylated cpg sequences and non-toxic lipopolysaccharides The present invention relates to immune stimulating composition comprising methylated bacterial chromosomal DNA fragments and non-toxic lipopolysaccharides. The composition of the present invention can be industrially applied the effective materials for treating cancers and adjuvant. ... 07/27/06 - 20060166922 - Polynucleotides targeted against the extended 5'-utr region of argininosuccinate synthase and uses thereof The present invention is based in part on the discovery that the upstream open reading frame (uORF) in the extended 5′-untranslated region (5′-UTR) argininosuccinate synthase (AS) mRNA species is functional, and when functional, limits overall AS expression as well as nitric oxide (NO) production. Thus, the extended 5′-UTR AS mRNA ... 07/27/06 - 20060166921 - Rnai modulation of rsv and therapeutic uses thereof The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based ... 07/27/06 - 20060166920 - Oligonucleotide based therapeutics The present invention relates to compositions comprising dsRNA. In particular, the present invention provides dsRNA comprising nucleotide sequence that is selectively complementary to bcl-xL mRNA sequence and that is not selectively complementary to bcl-xS mRNA sequence, recombinant nucleic acid comprising a vector and nucleic acid sequence for expressing bcl-xL dsRNA, ... 07/27/06 - 20060166919 - Rnai inhibition of ctgf for treatment of ocular disorders RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention. ... 07/27/06 - 20060166918 - Rnai modulation of mll-af4 and uses thereof The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides. ... 07/27/06 - 20060166917 - Differentiation and/or proliferation modulating agents and uses therefor The present invention discloses methods for modulating the differentiation and/or proliferation of mammary cells, especially of mammary epithelial cells, or for modulating the differentiation and/or proliferation of the lobuloalveolar system, or for modulating mammopoiesis and/or lactogenesis, or for modulating tumorigenesis in a cell which is associated with the reproductive system ... 07/27/06 - 20060166916 - Composite polynucleic acid therapeutics Compositions comprising therapeutic polynucleic acids and methods of use. The compositions comprise one or more polynucleic acids sequences having two or more features useful for treating diseases associated with cellular proliferation or growth. ... 07/27/06 - 20060166915 - Human coagulation factor vii polypeptides The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment. ... 07/27/06 - 20060166914 - Method of nucleic acid infusion A method of nucleic acid infusion, comprising the step (a) of bringing a nucleic acid, a hypertonic solution and cells into contact with each other and the step (b) of lowering the osmotic pressure of the hypertonic solution after the step (a). There is further provided a reagent for nucleic ... 07/27/06 - 20060166913 - Process for producing sirna It is an object of the present invention to develop an inexpensive and simple method for transcription and synthesis of siRNA. The present invention provides an oligonucleotide, which at least comprises, in a direction from the 5′-terminus to the 3′-terminus: (1) an antisense sequence of a target nucleic acid sequence; ... 07/27/06 - 20060166912 - Use of cytochrome p450 enzyme cyp2w1 as a drug target for cancer theraphy The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic ... 07/27/06 - 20060166911 - Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) The invention provides a human PDE11A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central ... 07/27/06 - 20060166910 - Rna-interference by single-stranded rna molecules The present invention relates to sequence and structural features of single-stranded (ss) RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation. ... 07/27/06 - 20060166909 - Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof Oligonucleotide inhibitors that inhibit expression of a mammalian MBD2/DNA demethylase (MBD2/dMTase) are provided. The oligonucleotide inhibitors can be used to inhibit the growth or proliferation of tumour cells in vitro and in vivo. The use of the oligonucleotide inhibitors in the treatment of cancer and methods of identifying potential target ... 07/27/06 - 20060166908 - Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof where A represents a direct bond, an alkylene group having 1 to 4 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1, R2, R3 and R4 each represent a hydrogen atom, a protective group for an amino group, a protective group for a ... 07/20/06 - 20060160764 - Limks as modifiers of p53 pathway and methods of use Human LIMK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LIMK are provided. ... 07/20/06 - 20060160763 - System for delivering therapeutic agents into living cells and cells nuclei A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically ... 07/20/06 - 20060160762 - Methods for the treatment, diagnosis, and prognosis of cancer We have discovered that antizyme inhibitor (AZI) is expressed at increased levels in highly proliferating cells. We have also discovered that inhibiting antizyme inhibitor, including inhibiting its expression, reduces the growth of cancer cells. The present invention is directed to the use of inhibitors of antizyme inhibitor for the treatment ... 07/20/06 - 20060160761 - Regulation of vascular endothelium using bmx tyrosine kinase Vascular endothelia are subject to atherosclerotic and arteriostenotic effects transduced by molecules, such as thrombin, IL-3 and VEGF which can lead to vessel occlusion or stenosis. An endothelial signaling pathway involving the Bmx tyrosine kinase contributes to normal endothelial nonthrombogenic, inflammatory and growth conditions of arterial vessels, and regulation of ... 07/20/06 - 20060160760 - Modulation of glucocorticoid receptor expression Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor ... 07/20/06 - 20060160759 - Influenza therapeutic The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The ... 07/20/06 - 20060160758 - Antisense modulation of cd40 ligand expression Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ... 07/20/06 - 20060160757 - Rna interference mediated inhibition hairless of (hr) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating hairless (HR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of hairless gene expression and/or activity ... 07/13/06 - 20060154890 - Immunostimulatory nucleic acids for the treatment of asthma and allergy The invention involves administration of an immunostimulatory nucleic acid alone or in combination with an asthma/allergy medicament for the treatment or prevention of asthma and allergy in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates ... 07/13/06 - 20060154889 - Polyfluorinated nucleoside analogs and methods of use thereof Nucleoside analogs comprising polyfluorinated benzene, pyrrole, pyridine, indole, isoindole, or benzoimidazole rings are shown to provide for selective base pairing with self, or other polyfluorinated analogs, in preference to native nucleic acid bases. The analogs of the invention stabilize the stacking of helices, and increase hydrophobicity when introduced into an ... 07/13/06 - 20060154888 - Lna oligonucleotides and the treatment of cancer The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5′-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3′, and preferably of the general formula 5′-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3′, wherein capital letters designate an LNA nucleotide analogue selected from β-D-oxy-LNA, β-D-thio-LNA, β-D-amino-LNA and α-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as ... 07/13/06 - 20060154887 - Use of apoptosis-specific eif-5a sirnas and antisense polynucleotides to inhibit/suppress an inflammatory response The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or ... 07/13/06 - 20060154886 - Regulatory elements in the 5' region of the vr1 gene A nucleic acid comprising a sequence section which modulates the expression of the VR1 receptor, a vector containing this nucleic acid and a host cell which is transformed with this vector are disclosed, along with related pharmaceutical formulations. Methods for modulating the expression of the VR1 receptor and the use ... 07/13/06 - 20060154885 - Modulation of slc26a2 expression Compounds, compositions and methods are provided for modulating the expression of SLC26A2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding SLC26A2. Methods of using these compounds for modulation of SLC26A2 expression and for diagnosis and treatment of disease associated with expression of SLC26A2 are provided. ... 07/13/06 - 20060154884 - Use of a vegf receptor gener or gene product The invention relates to the use of a VEGF receptor gene or receptor for the prevention or treatment of restenoses, ischaemia, arteriosclerosis and other cases of exuberant proliferation. The invention especially relates to the use thereof in therapy following balloon catheter treatment of the coronary vessels. The invention also relates ... 07/13/06 - 20060154883 - Nonsense-mediated mrna decay Disclosed are compositions and methods relating to nonsense mediated decay (NMD) particularly in the “pioneer” round of translation. The present invention provides methods of treating disorders relating to NMD and methods of screening substances for use in the study of or treatment of conditions relating to NMD. ... 07/13/06 - 20060154882 - Methods for blocking adipocyte differentiation and triglyceride accumulation with g-alpha-i3 inhibitors Methods for blocking adipocyte differentiation and triglyceride accumulation with inhibitors of G-alpha-i3 are provided. G-alpha-i3 inhibitors of the present invention include small molecules, antibodies, peptides (including dominant negative peptides) and antisense compounds, including ribozymes, inhibitory RNA molecules including siRNA molecules and antisense oligonucleotides. ... 07/06/06 - 20060148751 - Nucleic acid derivatives A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety ... 07/06/06 - 20060148750 - Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol Pharmaceutical compositions which comprise HIV Pol DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The pol-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and preferably express inactivated versions of the HIV Pol protein devoid of protease, ... 07/06/06 - 20060148749 - Novel treatment of neurodegenerative diseases by altering levels of trkb isoforms and/or trkc isoforms This invention relates to a method of treating or preventing neuro-degenerative disorders and neuro-developmental disorders by altering the ratio of the amount of full-length TrkB polypeptide to the amount of truncated TrkB polypeptides in a neuron or by altering the ratio of the amount of full-length TrkC polypeptide to the ... 07/06/06 - 20060148748 - Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (hgf/sf) or its receptor c-met The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are ... 07/06/06 - 20060148747 - Antisense antiviral compound and method for treating influenza viral infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds ... 07/06/06 - 20060148746 - Nucleic acid inhibitors of glutamate receptors The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that ... 07/06/06 - 20060148745 - Dna-based aptamers for human cathepsin g The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or ... 07/06/06 - 20060148744 - Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke The invention provides uses and methods for reducing brain damage from stroke. The uses comprise the use of an inhibitor of soluble epoxide hydrolase (sEH) for the manufacture of a medicament to reduce brain damage from stroke, as well as the use of cis-epoxyeicosatrienoic acid (EET) for that purpose. The ... 07/06/06 - 20060148743 - Rna interference mediated inhibition of histone deacetylase (hdac) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and ... 07/06/06 - 20060148742 - Polynucleotide delivery to cardiac tissue A method for delivering a polynucleotide to cardiac tissue, including substantially isolating the coronary venous circulation from systemic circulation, and introducing a polynucleotide into the isolated coronary venous circulation to effect localized transfection of cardiac tissue. The polynucleotide advantageously produces a therapeutic effect, such as increasing or decreasing the expression ... 07/06/06 - 20060148741 - Metastasis suppressor gene on human chromosome 8 and its use in the diagnosis, prognosis and treatment of cancer The invention provides an isolated or purified ribonucleic acid (RNA) molecule comprising a nucleotide sequence encoded by a human (Tey1) metastasis suppressor gene located at p21-p12 on chromosome 8 or a fragment thereof, wherein the isolated or purified RNA molecule comprises from about 10 to about 100 nucleotides. The invention ... 07/06/06 - 20060148740 - Mannose-6-phosphate receptor mediated gene transfer into muscle cells The invention relates to glycoside-compound conjugates for use in antisense strategies and/or gene therapy. The conjugates comprise a glycoside linked to a compound, in which the glycoside is a ligand capable of binding to a mannose-6-phosphate receptor of a muscle cell. For example the cells are muscle cells of a ... 07/06/06 - 20060148739 - Method of evaluating compound efficacious in treating obesity Examination of obesity or emaciation is performed based on expression levels of LCE gene or protein in a test tissue or a test cell or a polymorphism of the gene. Evaluation of compounds including screening of therapeutic agents for obesity or emaciation is performed utilizing the nature of LCE gene ... 07/06/06 - 20060148738 - Preventive for adhesion following abdominal surgery The present inventors discovered that oligonucleotides which suppress midkine expression and antibodies which suppress midkine activity can be used to prevent post-surgical intraperitoneal adhesions. ... 07/06/06 - 20060148737 - Wound healing method and kits Electroporation is used to enhance the wound-healing benefit provided by transfection of nucleic acids that encode cellular growth factors. Wounds which are amenable to the method include inter alia cutaneous lesions, muscular lesions, osseus lesions, burn wounds, and gastrointestinal anastamoses. Kits comprise electrodes and nucleic acids encoding cellular growth factors. ... 07/06/06 - 20060148736 - Device for assaying polymorphisms of gene xpd/ercc2 for the correct administration of chemotherapy for lung cancer The invention is encompassed in the technical sector of lung cancer treatment with antitumor drugs, and it specifically develops a diagnostic device which allows treating each patient with the most effective drug according to the polymorphism they show for the XPD gene. The assay device of the invention is based ... 07/06/06 - 20060148735 - Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors The present invention relates to methods for treating or preventing cardiac disorders such as heart failure, by administering to a mammal a therapeutically effective amount of an FADD inhibitor. According to the present invention, the FADD inhibitor is anti-apoptotic, anti-inflammatory, or both. Also disclosed are screening methods that make use ... 07/06/06 - 20060148734 - Diaminoacid-aminoacid-polyamine based gemini surfactant compounds Diaminoacid-polyamine:peptide-based gemini compounds are disclosed. The compounds are based on diaminoacid-polyamine or diaminoacid-aminoacid-polyamine backbone with peptide groups and optionally hydrocarboxyl groups linked thereto. Uses of the diaminoacid-polyamine:peptide-based gemini compounds and methods for their production are also disclosed. ... 06/29/06 - 20060142236 - Antisense oligonucleotide modulation of raf gene expression Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. ... 06/29/06 - 20060142235 - Method of reducing and treating uvb-induced immunosuppression Methods of preventing and/or treating UV-induced immunosuppression by administration of immune response modifier compounds are disclosed herein. Suitable immune response modifier compounds include agonists of one or more TLRs. ... 06/29/06 - 20060142234 - Injectable non-aqueous suspension The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions. ... 06/29/06 - 20060142233 - Gene expression and genetic changes implicated in alcoholism Polynucleotides, polypeptides, kits and methods are provided related to regulated genes characteristic of alcoholism. ... 06/29/06 - 20060142232 - Oligomeric compositions and methods The activated oligomer compounds described herein are capable of forming bio-reversible covalent bonds with plasma proteins, in particular with human serum albumin. The plasma protein-oligomer complexes of the present invention exhibit enhanced cellular entry and significantly enhanced serum half-life. ... 06/29/06 - 20060142231 - Dna damage repair inhibitors for treatment of cancer DNA Damage Repair Inhibitors for Treatment of Cancer The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in ... 06/29/06 - 20060142230 - Double-stranded ribonucleic acid molecules having ribothymidine The invention relates to a double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5′-methyl-pyrimidine, and a method of using such modified dsRNA molecule to increase stability of RNA when in contact with a ... 06/29/06 - 20060142229 - Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double ... 06/29/06 - 20060142228 - Methods and compositions concerning sirna's as mediators of rna interference The present invention concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, ... 06/29/06 - 20060142227 - Amphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier The invention provides molecules comprising a nucleic acid, a hydrophobic moiety and a positively charge moiety, useful in the delivery of a nucleic acid sequence across a cellular membrane. The invention further relates to the use of these molecules for the delivery of a nucleic acid sequence to the brain ... 06/29/06 - 20060142226 - Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene ... 06/29/06 - 20060142225 - Rna interference mediated inhibition of cyclin dependent kinase-2 (cdk2) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CDK2 gene expression ... 06/29/06 - 20060142224 - Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds. ... 06/29/06 - 20060142223 - Methods for xenotopic expression of nucleus-encoded plant and protist peptides and uses thereof The present invention provides a method for introducing a functional peptide encoded by a plant or protist nucleic acid sequence into a mitochondrion of a mammalian cell, and a pharmaceutical composition comprising the nucleic acid sequence. The present invention also provides a method for correcting a phenotypic deficiency in a ... 06/29/06 - 20060142222 - Novel gene relating to fibrotic conditions This discloses a novel human or rat polypeptide useful in improving and/or preventing organ fibrosis and a polynucleotide encoding the aforementioned polypeptide, an expression vector containing the aforementioned polynucleotide, and a cell transfected with the aforementioned expression vector. The aforementioned polynucleotide shows a remarkable decrease in the expression dose in ... 06/29/06 - 20060142221 - Vaccine The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions ... 06/29/06 - 20060142220 - Protein modification The present invention relates to a method for changing the half-life of a glycosylated compound by the modification of its O-linked carbohydrates. This modification is preferably carried out enzymatically and aimed at extending the half-life of the compound. Both in vivo and in vitro modification protocols may be used. ... 06/29/06 - 20060142219 - Pharmaceutical compositions comprising an hiv envelope protein and cd4 Pharmaceutical composition for treating/preventing HIV comprising (i) a polynucleotide encoding HIV envelope protein and (ii) a polynucleotide encoding CD4 receptor protein or; (i) a polynucleotide encoding HIV envelope protein and (ii) a CD4 receptor protein or; a fixed cell expressing an HIV envelope protein complexed with a CD4 receptor protein. ... 06/29/06 - 20060142218 - Method of controlling telomere length A method of controlling telomere length wherein the method comprises introducing into a cell a DNA encoding Mre11 protein or a DNA encoding a protein comprising Mre11 protein wherein a part of the nuclease domain, the C-terminal domain or the whole thereof is modified or deleted. ... 06/22/06 - 20060135462 - N8- and c8-linked purine bases and structurally related heterocycles as universal nucleosides used for oligonucleotides hybridization The present invention is directed to a nucleic acid binding compound comprising N8- or C8-linked purine bases or structurally related heterocycles, a compound useful for the preparation of such compound, a binding product of this nucleic acid binding compound with a nucleic acid, a method for the determination of a ... 06/22/06 - 20060135461 - Reduction of hair growth Mammalian hair growth is reduced by topically applying a composition including a survivin inhibitor. ... 06/22/06 - 20060135460 - Methods, assays and compositions for treating retinol-related diseases Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and/or prevention of age-related macular degeneration and/or dystrophies, metabolic disorders, ... 06/22/06 - 20060135459 - Targeted innate immunity Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of ... 06/22/06 - 20060135458 - Antiviral oligonucleotides Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length and include chemical modifications, such as modified internucleotidic linkages and modifications at the 2′-position of the ribose moieties. Also described are methods ... 06/22/06 - 20060135457 - Methods for constructing antibiotic resistance free vaccines The present invention provides DNA vaccines comprising an antibiotic resistance gene-free plasmid, methods of generating same, and methods for treating a disease agent, comprising same. ... 06/22/06 - 20060135456 - Methods and compositions for rna interference The present invention provides methods for attenuating gene expression in a cell, especially in a mammalian cell, using gene-targeted double stranded RNA (dsRNA), such as a hairpin RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a ... 06/22/06 - 20060135455 - Methods and compositions for the inhibition of gene expression The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers. ... 06/22/06 - 20060135454 - Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing the immune response caused by immunostimulatory oligonucleotide compounds. ... 06/22/06 - 20060135453 - Down-regulation of target-gene with pei/single-stranded oligoribonucleotide complexes The present invention provides methods for the downregulation of target genes by an RNA interference mechanism using short single stranded RNA and a cationic polymer, such as linear PEI. ... 06/22/06 - 20060135452 - Methods for treating or preventing angiogenesis-dependent symptoms A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including ... 06/22/06 - 20060135451 - Vaccine The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines that encode the HCV Core protein and a polynucleotide sequence that encodes at least ... 06/22/06 - 20060135450 - Combinations of antisense oligonucleotides directed against thymidylate synthase mrna and uses thereof Effective combinations of antisense oligonucleotides directed against thymidylate synthase mRNA are provided for use in cancer therapies. Combinations of antisense oligonucleotides have enhanced activity compared to the activity of the individual antisense oligonucleotides when used alone. The combinations may be used in conjunction with one or more chemotherapeutic agents to ... 06/22/06 - 20060135449 - Decoy compositions for treating and preventing brain diseases and disorders The present invention provides introduction of NF-κB decoy oligodeoxynucleotide into rat cranial nerve through a carotid artery during global brain ischemia. Polymerase chain reaction demonstrated that one hour after global brain ischemia, transfected NF-κB decoy oligodeoxynucleotide effectively suppressed expression of tumor necrosis factor α, interleukin 1β and intracellular adhesion molecule ... 06/15/06 - 20060128651 - Methods and compositions for modulating drug activity through telomere damage The invention provides methods and compositions for modulating the activity of therapeutic agents for the treatment of a cancer by administering one or more agents that (either alone or in combination) induces telomere damage and inhibits telomerase activity in the cancer cell. The method initially uses, e.g., a telomere damage-inducing ... 06/15/06 - 20060128650 - Allele-specific rna interference Human diseases caused by dominant, gain-of-function mutations develop in heterozygotes bearing one mutant and one wild-type copy of a gene. Because the wild-type gene often performs important functions, whereas the mutant gene is toxic, any therapeutic strategy must selectively inhibit the mutant while retaining wild-type gene expression. The present invention ... 06/15/06 - 20060128649 - Aptamer-mediated regulation of gene expression This invention provides methods of regulating gene expression. An aptamer is positioned in a nucleic acid molecule along with a sequence encoding a transcriptional regulatory polypeptide. The aptamer disrupts translation of the transcriptional regulatory polypeptide when contacted with an aptamer-binding ligand. Gene expression levels can be either increased or decreased ... 06/15/06 - 20060128648 - Genetic suppression and replacement A strategy for suppressing specifically or partially specifically an endogenous gene and introducing a replacement gene, said strategy comprising the steps of: 1. providing suppressing nucleic acids or other suppression effectors able to bind to an endogenous gene, gene transcript or gene product to be suppressed and 2. providing genomic ... 06/15/06 - 20060128647 - Novel oligonucleotides and treating cardiac disorders by using the same Novel oligonucleotides and methods of treating a cardiac disease or disorder using the same are provided. The oligonucleotides are useful in modulating the expression of the connexin 43 protein and may be combined with other biologically active agents and compositions to treat cardiac disease. Methods of modulating connexin expression include ... 06/15/06 - 20060128646 - Antisense design A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or ... 06/15/06 - 20060128645 - Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit The present invention is to provide a method of treatment which inhibits proliferation and invasion of brain tumor cells in developing animal brain tumor cells, and a method for measuring proliferation/invasion activity of brain tumor cells, in the brain tumor cells, preferably, in glioblastoma. Proliferation and invasion of brain tumor ... 06/15/06 - 20060128644 - Use of mob-5 in pain The invention discloses Mob-5 as a suitable target for the development of new therapeutics to treat or ameliorate chronic pain. The invention relates to methods to treat and/or ameliorate chronic pain and pharmaceutical compositions therefor comprising modulators with inhibitory or stimulatory effect on Mob-5 activity and/or Mob-5 gene expression. The ... 06/08/06 - 20060122142 - Dna vaccines for farm animals, in particular bovines and porcines in which R1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group, this lipid being preferably DMRIE. ... 06/08/06 - 20060122141 - Treatment of cancer by inhibition of igfbp's and clusterin Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, ... 06/08/06 - 20060122140 - In vitro and in vivo silencing of human c-myc oncogene expression by poly-dnp-rna The present invention provides antisense oligoribonucleotides with sequences that recognize and bind to the c-myc gene or c-myc mRNA, where one or more sugar residues of the oligoribonucleotides are modified by the substitution of DNP at the 2′-O position. The antisense oligoribonucleotides can be used for inhibiting the growth of ... 06/08/06 - 20060122139 - Inducible systems and methods for controlling sirna expression An inducible system and methods for controlling expression of siRNA are provided. An inducible system for producing siRNA only in the presence of HIV TAT, and methods for inhibiting HIV-1 gene expression in cells comprising such inducible system also are provided. ... 06/08/06 - 20060122138 - Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of non-neoplastic hyperproliferative epithelial and/or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and/or aberrant angiogenesis. Non-limiting examples of ... 06/08/06 - 20060122137 - 5'-methylpyrimidine and 2'-o-methyl ribonucleotide modified double-stranded ribonucleic acid molecules The invention relates to a double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, at least one 5′-methyl-pyrimidine and at least one 2′—O-methyl ribonucleotide, and a methods of using such modified dsRNA molecule to increase stability of a siRNA molecule when in contact with ... 06/08/06 - 20060122136 - Effective and stable dna enzymes The present invention relates to DNA enzymes of type 10-23 with certain modifications of specific nucleotides in the core sequence rendering the DNA enzymes particularly stable and additionally exhibiting substantially the same or a higher cleavage efficiency with respect to their substrate when compared against the corresponding unmodified DNA enzymes. ... 06/08/06 - 20060122135 - Method for treating or preventing a neural disorder with a neurotrophic growth factor There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid ... 06/08/06 - 20060122134 - Functional correction of the -786c/t variance of the human enos gene The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 34 and their use as pharmaceutical agents. The present invention also discloses a method for diagnosis of the −786C/T-variance in the eNOS-gene. ... 06/08/06 - 20060122133 - Antisense modulation of vegf co-regulated chemokine-1 expression Antisense compounds, compositions, and methods are provided for modulating the expression of VEGF Co-regulated chemokine-1 (VCC-1). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding VCC-1. Methods of using these compounds for modulation of VCC-1 expression and for treatment of diseases associated with expression of VCC-1 ... 06/08/06 - 20060122132 - Use of murine genomic regions identified to be involved in tumor developement for the development of anti-cancer drugs and diagnosis of cancer The present invention relates to murine genomic regions, identified by retroviral insertional tagging of mice as being involved in tumor development, in particular leukemia development, as well as human homologues thereof, and to the use of these genomic regions for the identification and development of anti-cancer drugs, such as small ... 06/08/06 - 20060122131 - Methods for blocking adipocyte differentiation and triglyceride accumulation with transcription factor dp-1 inhibitors Methods for blocking adipocyte differentiation and triglyceride accumulation with inhibitors of Transcription factor Dp-1 are provided. Transcription factor Dp-1 inhibitors of the present invention include small molecules, antibodies, peptides (including dominant negative peptides) and antisense compounds, including ribozymes, inhibitory RNA molecules including siRNA molecules and antisense oligonucleotides. ... 06/08/06 - 20060122130 - Method for rendering a system immunologically compatible utilizing a nucleic acid construct, a nucleic acid construct for inhibiting or regulating the function of an immune response (ir) gene and an immunologically compatible system containing a nucleic a This invention provides a method for preparing an immunologically compatible system, e.g., organism, organ, tissue, or cells by appropriate genetic intervention which can take the form of introducing into the cells of such a system, a nucleic acid construct which, when present in a cell, inhibits or regulates the function ... 06/01/06 - 20060116344 - Remedy and preventive for diseases caused by nf-kb Administration of a decoy, i.e. a compound which specifically antagonizes the nucleic acid domain to which NF-κB is bound, is effective in the treatment and prevention of diseases caused by the transcriptional regulatory factor NF-κB, such as ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia. ... 06/01/06 - 20060116343 - Sphingosine kinase-1 mediates gene expression regulation of a monocyte chemoattractant protein-1 gene The present invention relates to methods of identifying, monitoring, and using compounds that regulate the biological activity of Sphingosine kinase-1. ... 06/01/06 - 20060116342 - Protective immunity or immunological tolerance induced with rna, particularly total cellular rna Effective anti-tumor immunity is induced in mice utilizing RNA-pulsed epidermal cells (EC) for in vivo immunization or by injecting RNA intradermally into naïve mice. A vaccine comprising total cell RNA and a pharmaceutically acceptable carrier for inducing an immune response to reduce or prevent the occurrence of a tumor. ... 06/01/06 - 20060116341 - Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an ... 06/01/06 - 20060116340 - Herpesvirus ribozymes and vectors Hammerhead ribozymes that target components critical to HSV replication (ICP4, UL20, UL30, and UL54) were synthesized and shown to efficiently cleave target RNA encoding a portion of these components in in vitro assays. Several cloned cell lines stably expressing these ribozymes were established. HSV-mediated plaque formation was dramatically reduced in ... 06/01/06 - 20060116339 - Antisense modulation of purinoreceptor p2x3 The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of P2X3. The compositions comprise antisense oligonucleotides, particularly antisense oligonucleotides targeted to nucleic acids encoding P2X3. ... 06/01/06 - 20060116338 - Mammalian early developmental regulator gene This disclosure encompasses the edr3 polynucleotide, polypeptides encoded by the edr3 gene and fragments thereof. This disclosure also encompasses homologues of the edr3 gene from mammals, in particular from humans. In addition, this disclosure encompasses the use of edr3 polynucleotides, edr3 proteins and polypeptides, and antibodies to the edr3 protein ... 05/25/06 - 20060111316 - Treatment of inflammatory, non-infectious, autoimmune, vasculitic, degenerative vascular, host-v-graft diseases, alzheimers disease, and amyloidosis using mammalian, dsdna vaccination The present invention relates generally to compositions and methods using mammalian, dsDNA (Double Stranded Deoxyribonucleic Acid) vaccination for the induction and maintenance of regulator suppressor T cells resulting in suppression of non infectious, and post infectious, inflammatory, allergic, auto-immune, vasculitic, certain degenerative vascular, and graft versus host diseases, with or ... 05/25/06 - 20060111315 - Method for inhibition of pathogenic microorganisms Disclosed is a method for inhibiting the growth of a microorganism by high efficiency transfection of a human host cell with a nucleic acid encoding an antimicrobial agent, such that the host cell expresses the antimicrobial agent effective to inhibit growth of the microorganism. ... 05/25/06 - 20060111314 - Method for treating or preventing metastasis of colorectal cancers Disclosed are methods of detecting metastasis of colorectal cancer using differentially expressed genes. Also disclosed are methods of identifying agents for treating colorectal cancer or preventing metastasis of colorectal cancer. ... 05/25/06 - 20060111313 - Nell-1 enhanced bone mineralization This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The HELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, HELL-1 can be used to facilitate repair of bone fractures and/or to generally increase ... 05/25/06 - 20060111312 - Antigene locks and therapeutic uses thereof An oligonucleotide based therapeutic strategy, called anti-gene locks, is described which specifically kills cells based on their genotype. The strategy employs oligonucleotides with arms and a backbone that are complementary to both strands of the gene target. Anti-gene locks bind in vitro in a sequence dependent fashion and inhibit DNA ... 05/18/06 - 20060105983 - Cytotoxic agents A method of killing a cell that is lacking in effective p53 protein activity, particularly as compared to wild type, is provided characterized in that it comprises delivering to the cell a single stranded DNA including a portion with at least one base, internally located with respect to any 3′ ... 05/18/06 - 20060105982 - Non-invasive gene targeting to ocular cells Liposomes containing therapeutic genes are conjugated to multiple targeting agents to provide transport of the encapsulated gene across the blood-retinal barrier and the plasma membrane of ocular cells. Once across the blood-retinal barrier and ocular cell membrane, the encapsulated gene expresses the encoded therapeutic agent within the ocular cells to ... 05/18/06 - 20060105981 - Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting substance against wilms' tumor gene (wt1) The present invention relates to therapeutic agents for treatment of solid tumors comprising an expression-inhibiting substance (an antisense oligonucleotide derivative, a WT1 mutant gene, a WT1 mutant protein, a low molecular weight substance, and the like) against the Wilms' tumor gene (WTI). ... 05/18/06 - 20060105980 - Aptamer therapeutics useful in the treatment of complement-related disorders The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders. ... 05/18/06 - 20060105979 - Synergistic inhibition of vegf and modulation of the immune response The invention provides methods and compositions for treating asthma and allergy by inhibiting VEGF expression and modulating the immune system from a Th2 response to a Th1 response. ... 05/18/06 - 20060105978 - Dose forms The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, ... 05/18/06 - 20060105977 - Desmoglein 4 is a novel gene involved in hair growth This invention provides methods and compositions for inhibiting the expression of desmoglein 4. This invention also provides pharmaceutical compositions for inhibiting hair growth in a subject. ... 05/18/06 - 20060105976 - Rnai modulation of apob and uses thereof The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides. ... 05/18/06 - 20060105975 - Aptamer-mediated intracellular delivery of therapeutic oligonucleotides Materials and methods are provided to modulate, in a controlled manner, the intracellular deliver of therapeutic agents, including therapeutic oligonucleotides using nucleic acid aptamers. ... 05/18/06 - 20060105974 - Conjugates of photosensitizers and oligonucleotides for selective photochemiotherapy This invention relates to oligonucleotide targeting agents and their use in the treatment of diseased cells by selective photochemotherapy (PCT). PCT is a method of treating human diseases and disorders, bacteriological indications and other pathological conditions. PCT is based on the topical or systemic application of a photosensitizing agent, a ... 05/18/06 - 20060105973 - Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression Antisense compounds, compositions and methods are provided for modulating the expression of hydroxysteroid 11-beta dehydrogenase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hydroxysteroid 11-beta dehydrogenase 1. Methods of using these compounds for modulation of hydroxysteroid 11-beta dehydrogenase 1 expression and for treatment of ... 05/04/06 - 20060094684 - Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration ... 05/04/06 - 20060094683 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 05/04/06 - 20060094682 - Kinase inhibitors for the treatment of diabetes and obesity The present invention discloses a method of treating an individual or animal with diabetes and/or obesity. The method comprises administering to the individual or animal a therapeutically effective amount of a protein tyrosine kinase inhibitor. Preferably, the preventative and therapeutic methods of the present invention involve administering—to a mammal in ... 05/04/06 - 20060094681 - Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... 05/04/06 - 20060094680 - Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... 05/04/06 - 20060094679 - Method of preventing or treating liver disease An object of the present invention is to provide a method of preventing or treating liver disease, particularly non-alcoholic fatty liver disease, hepatic fibrosis, cirrhosis, or liver cancer. The present invention is directed to a method of preventing or treating liver disease comprising administering to a patient in need thereof ... 05/04/06 - 20060094678 - Nuclease resistant double-stranded ribonucleic acid This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene. ... 05/04/06 - 20060094677 - Inhibition of apoptosis-specific eif-5a (eif-5a1) with antisense oligonucleotides and sirna as anti-inflammatory therapeutics The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5A1, nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of apoptosis-specific eIF-5A. The invention also relates to suppressing or ... 05/04/06 - 20060094676 - Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity Elevated ETRB activity, BCL-2A1 activity and/or PARP-3 activity was detected in cancer cells, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating cancer by reducing or inhibiting the ETRB activity, BCL-2A1 activity and/or PARP-3 activity. Also provided are methods of ... 05/04/06 - 20060094675 - Method for the repair of mutated rna from genetically defective dna and for the specific destruction of tumor cells by rna trans-splicing, and a method for the detection of naturally trans-spliced cellular rna Methods and products for the repair of genetically defective DNA in the region of a mutated exon, for the specific destruction of tumor cells, and for the identification of naturally trans-spliced RNA. The methods inter alia are based on the utilization of cellular RNA splicing components. ... 05/04/06 - 20060094674 - Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms The invention features methods and compositions including an mTOR inhibitor and a tyrosine kinase inhibitor for reducing the proliferation of and enhancing the apoptosis of neoplastic cells. The addition of an MEK inhibitor to this combination further enhances the effectiveness of this therapeutic method. ... 05/04/06 - 20060094673 - Polymer surfactants for gene therapy applications A composition and method capable of delivering pharmaceutical or biomedical materials includes a tri-block surfactant having a hydrophilic block, a charged water-soluble block and a hydrophobic block. ... 05/04/06 - 20060094672 - Compositions and methods of use of targeting peptides against placenta and adipose tissues The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 OR SEQ ID NO:144. The peptides may be attached to various therapeutic agents ... 04/27/06 - 20060089326 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 04/27/06 - 20060089325 - Antisense modulation of ptp1b expression Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The ... 04/27/06 - 20060089324 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated ... 04/27/06 - 20060089323 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated ... 04/27/06 - 20060089322 - Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies The present invention provides antisense oligonucleotides useful for identifying drug targets for cancer therapies and for enhancing current cancer therapies. The oligonucleotides of the invention are complementary to thymidylate synthase mRNA and affect expression of at least one other gene. For the enhancement of cancer therapies, such antisense oligonucleotides can ... 04/27/06 - 20060089321 - Cks1 inhibitors Inhibitors of human Cks1 and human Skp2, including antisense oligonucleotides, methods, and compositions specific for human Cks1 and human Skp2, are provided. Methods of using the compositions for modulating Cks1 expression and Skp2 expression, and for regulating cell growth, particularly tumor cell growth, are also provided. ... 04/27/06 - 20060089320 - Modulation of type iiß phosphoinositide phosphate kinase The invention provides methods for modulating type IIβ phosphoinisitide phosphate kinase (PIPKIIβ) activity for treating PIPKIIβ-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKIIβ-associated disorders. ... 04/20/06 - 20060084623 - Dna vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive ... 04/20/06 - 20060084622 - Angiogenic factor and use thereof in treating cardiovascular disease The present invention relates to a novel VEGF protein product, and nucleic acid encoding the novel protein product, comprising exons 1-6 and 8 of the VEGF gene, and its use thereof in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF145 has been ... 04/20/06 - 20060084621 - Compositions and methods for inhibiting expression of anti-apoptotic genes The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as ... 04/20/06 - 20060084620 - Rna interference in respiratory epitheial cells The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules. ... 04/20/06 - 20060084619 - Novel neurotrophic factor protein and uses thereof The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is ... 04/20/06 - 20060084618 - Adiponectin promoter and use thereof The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method ... 04/20/06 - 20060084617 - Methods for delivery of nucleic acids This invention features methods and compositions for delivery of nucleic acids (e.g., DNA, RNA, PNA, and hybrids thereof) to cells. The nucleic acid delivery complexes of the invention permit biologically active nucleic acids to be delivered to cells and organisms in vitro and in vivo in a manner and form ... 04/13/06 - 20060079477 - High affinity nucleic acid ligands of complement system proteins Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 ... 04/13/06 - 20060079476 - Method for enhancing production of isoprenoid compounds The present invention provides methods of producing an isoprenoid or an isoprenoid precursor in a genetically modified host cell. The methods generally involve modulating the level of hydroxymethylglutaryl-CoA (HMG-CoA) in the cell, such that the level of HMG-CoA is not toxic to the cell and/or does not substantially inhibit cell ... 04/13/06 - 20060079475 - Methods and compositions for modulating cardiac contractility Methods and compositions are provided for modulating cardiac contractility by regulating transcription of the phsopholamban gene using engineered zinc finger proteins. ... 04/13/06 - 20060079474 - Analogs of trna synthetase fragments and uses thereof The present invention relates to analogs of tRNA synthetase fragments and various uses thereof. In some embodiments, the tRNA synthetase fragment is a human tRNA synthetase fragment. In some embodiments, the tRNA synthetase fragment is a tryptophanyl tRNA synthetase fragment. The analogs herein can be used to modulate angiogenesis. ... 04/13/06 - 20060079473 - Multi-unit complexes and uses thereof The present invention relates to a multi-unit complex of a tRNA synthetase fragment. The multi-unit complexes can comprise of two or more monomer units. Two monomer units can be covalently or non-covalently linked. The multi-unit complexes may further be used, for example, in pharmaceutical formulation to modulate angiogenesis. ... 04/13/06 - 20060079472 - Methods for treating angiogenesis The present invention relates to methods for treating an angiogenesis mediated condition. In particular, the present invention relates to the use of a multi-unit complex that includes a tRNA synthetase fragment or a homolog or analog thereof to treat such conditions. In some embodiments, the multi-unit complex is a dimer ... 04/13/06 - 20060079471 - Snornai-small nucleolar rna degradation by rna interference in trypanosomatids Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as ... 04/13/06 - 20060079470 - Combined dna vaccine and biological modifiers for cancer therapy The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well ... 04/13/06 - 20060079469 - Anti-restenosis agent An anti-restenosis agent comprises a phosphorothioate-modified oligonucleotide includes at least on hairpin loop and a TG sequence. The hairpin loop preferably has the sequence CAG CGA AGC. Especially preferred oligonucleotides are ones which include a sequence selected from TGGGG TGGGG T GGGGT GGGGT CAG CGA AGC (SEQ ED NO: 4) ... 04/06/06 - 20060074045 - Vector for transfection of eukaryotic cells Vectors comprising a nucleic acid, a nucleic acid binding polymer, a vesicle and a membrane active polypeptide are described. Preferred vectors facilitate transfection and/or reduce cytotoxicity. Methods of making the vectors and methods of using the vectors to transfect cells and/or treat a patient in need of gene therapy are ... 04/06/06 - 20060074044 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof the correspond to a novel human secreted stem cell growth factor-like polypeptide. These polypeptides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal ... 04/06/06 - 20060074043 - Antisense modulation of matrix metalloproteinase 1 expression Antisense compounds, compositions and methods are provided for modulating the expression of matrix metalloproteinase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding matrix metalloproteinase 1. Methods of using these compounds for modulation of matrix metalloproteinase 1 expression and for treatment of diseases associated with ... 04/06/06 - 20060074042 - Highly hypoxia-specific gene expression system for ischemic gene therapy Compositions and methods for treating ischemic diseases, such as ischemic heart disease, are disclosed. Plasmid pEpo-SV-VEGF-EpoUTR comprises an erythropoietin enhancer and an erythropoietin 3′ untranslated region operably coupled to a vascular endothelial growth factor (VEGF) coding segment. High expression of VEGF under hypoxic conditions is obtained. Similar plasmids, with anticancer ... 04/06/06 - 20060074041 - Antisense and antigene therapeutics with improved binding properties and methods for their use The present invention is directed to novel nucleic acid molecules and methods for their use. More specifically, the novel nucleic acid molecules of the present invention are capable of tightly and specifically interacting with a target molecule of interest not only through standard Watson-Crick base pairing, but also through additional ... 04/06/06 - 20060074040 - Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the ... 04/06/06 - 20060074039 - Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. ... 04/06/06 - 20060074038 - Her-2 neu dna vaccine having anti-cancer activity The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic ... 04/06/06 - 20060074037 - Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine ... 04/06/06 - 20060074036 - Agents for gene therapy of cerebrovascular disorders The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and ... 04/06/06 - 20060074035 - Dinucleotide inhibitors of de novo rna polymerases for treatment or prevention of viral infections Contemplated dinucleotide compounds have a general structure of A-B and inhibit synthesis of an RNA-dependent polymerase that initiates RNA replication de novo. In preferred dinucleotides, A comprises a purine or modified purine heterocyclic base and B comprises a pyrimidine or modified pyrimidine heterocyclic base. ... 04/06/06 - 20060074034 - Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof This invention is in the area of cobalamin-mediated delivery of nucleic acids and analogs and derivatives thereof to a host to affect gene expression. ... 04/06/06 - 20060074033 - Secreted and transmembrane polypeptides and nucleic acids encoding the same The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides ... 03/30/06 - 20060069058 - Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β-peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease. ... 03/30/06 - 20060069057 - Medicaments containing xenogeneic oligo- and/or polyribonucleotides The invention relates to medicaments that contain xenogenic oligo- or/and polyribonucleotides as the effective component. The invention further relates to the use of said xenogenic oligo- or/and polyribonucleotides for treating herpesviridae infections and skin tumors. ... 03/30/06 - 20060069056 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a ... 03/30/06 - 20060069055 - Delivery of polynucleotides The present invention concerns methods and formulations for non-parental delivery of nucleic acid molecules to cells. In particular, the present invention relates to methods and formulations that enhance the transport of poly- and oligonucleotides across biological membranes. ... 03/30/06 - 20060069054 - Compositions and methods for the therapy and diagnosis of breast cancer Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. ... 03/30/06 - 20060069053 - Methods and compositions for enhancing cartilage repair The invention relates to methods of enhancing repair of a cartilage and/or inducing formation of a cartilage by administering a cell, which expresses a factor of the T-box family, which includes inter-alia the brachyury. In another embodiment, the invention relates to an engineered cell, which is transfected with a vector ... 03/30/06 - 20060069052 - Dna vaccines that expresses mutant adp-ribosyitransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity The present invention provides DNA vaccines that direct the coincident expression of vaccine antigens coincidently with mutant ADP-ribosyltransferase toxins (mARTs), which display reduced, or are devoid of, ADP-ribosyltransferase activity, and methods for vaccinating animals with the same. In particular, the present invention provides DNA vaccines that direct the coincident expression ... 03/30/06 - 20060069051 - Ache antisense oligonucleotide as an anti-inflammatory agent Disclosed is a novel use for AChE antisense oligonucleotides as anti-inflammatory agents, wherein said oligonucleotides are preferably as denoted by SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:7. Methods of treatment of inflammatory conditions, as well as fever, and particularly inflammation-associated neuropathies such as Guillain-Barré Syndrome, are described. ... 03/30/06 - 20060069050 - Methods and compositions for mediating gene silencing The present invention provides methods of conducting RNAi using siRNAs that are sequentially administered as single-stranded oligonucleotides. The siRNAs can be canonical or have non-canonical ends. The compositions and methods of the invention can bypass activation of interferon pathways and yet still efficiently and specifically activate RNAi/gene silencing. In another ... 03/30/06 - 20060069049 - Methods and reagents related to foxo The present invention relates to regulating the activity of Foxo and prevention and treatment of diseases associated with aberrant Foxo activity. ... 03/23/06 - 20060063734 - 4,7-dichlorofluorescein dyes as molecular probes Long wavelength, narrow emission bandwidth fluorecein dyes are provided for detecting spacially overlapping target substances. The dyes comprise 4,7-dichlorofluoresceins, and particularly 2′,4′,5′,7′-tetrachloro-4,7-dichloro-5- (and 6-)carboxyfluoresceins. Methods and kits for using the dyes in DNA analysis are provided. ... 03/23/06 - 20060063733 - Methods of reducing an immune response The invention relates to methods of reducing an immune response to a transgene product in a mammal by co-administration of a small-interfering ribonucleic acid (siRNA) molecule that temporarily inhibits or reduces transgene expression, wherein the siRNA is administered in an amount, and for a period of time, sufficient to reduce ... 03/23/06 - 20060063732 - Compositions and methods for gene therapy The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) physically linked to a transfection agent for use in embolization gene therapy. The present invention further relates to methods of embolization gene ... 03/23/06 - 20060063731 - In vivo inhibition of hepatitis b virus A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of ... 03/23/06 - 20060063730 - Enhanced antisense oligonucleotides Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened ... 03/23/06 - 20060063729 - Ocular gene therapy The invention relates to methods of ocular gene therapy. ... 03/23/06 - 20060063728 - Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, ... 03/23/06 - 20060063727 - Tr4/tr2 response elements Disclosed are compositions and methods related to TR2 and TR4. ... 03/16/06 - 20060058258 - Gene transcription and ionizing radiation: methods and compositions The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of ... 03/16/06 - 20060058257 - Influencing angiogenesis using cd66a The invention relates to a method of influencing angiogenesis by administering a of a compound in a pharmaceutically compatible carrier selected from the group consisting of (i) CD66a, a CD66a variant, CD66a fragments or CD66a-derived glycostructures, or CD66a ligands, or (ii) of anti-CD66a specific antibodies and anti-sense oligonucleotides. ... 03/16/06 - 20060058256 - Oligoribonucleotides for the treatment of degenerative skin conditions by rna interference The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mRNA enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders. ... 03/16/06 - 20060058255 - Rnai-based therapeutics for allergic rhinitis and asthma The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of ... 03/16/06 - 20060058254 - Immunostimulatory sequence oligonucleotides and methods of using the same The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides. ... 03/16/06 - 20060058253 - Methods to reprogram splice site selection in pre-messenger rnas The present invention relates to a method of modulating splice site selection, splicing and alternative, the method comprising the step of hybridizing an oligonucleotide-protein conjugate to a target pre-mRNA molecule in a cell or cell extract, wherein the oligonucleotide-protein conjugate comprises an oligonucleotide moiety which comprises at least two distinct ... 03/16/06 - 20060058252 - Methods and materials for treating human papillomavirus infections The invention provides methods and materials related to treating HPV infections (e.g., HPV infections of cutaneous and mucosal epithelial cells) and HPV-associated conditions (e.g., cervical dysplasia, HPV-associated cervical carcinomas, oral mucosal papilloma cancers, laryngeal papilloma cancers). ... 03/16/06 - 20060058251 - Methods for treating and preventing infectious disease Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant. ... 03/09/06 - 20060052329 - Regulation of human p2y1-like g protein-coupled receptor Reagents which regulate human P2Y1-like G protein-coupled receptor can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, CNS diseases such as Parkinson's ... 03/09/06 - 20060052328 - Connective tissue growth factor-2 The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for stimulating angiogenesis enhancing the repair of ... 03/09/06 - 20060052327 - Cell specific gene silencing using cell-specific promoters in vitro and in vivo Cell-specific methods for silencing genes using double-strand inhibitory RNA (iRNA) are provided, as are constructs for carrying out the methods. ... 03/09/06 - 20060052326 - Werner's syndrome helicase as a target for anti -hiv/aids therapy Werner's Syndrome helicase (WRN) interacts in Tat/TAR-RNA chromatin-remodeling complexes assembled on the HIV-1 LTR to promote transcriptional activation and viral replication. WRN markedly increases basal HIV-1 transcription and synergizes with Tat to support LTR trans-activation. Inhibition of WRN functions, through expression of the trans-dominant-negative WRNK577M mutant, potently represses HIV-1 LTR ... 03/09/06 - 20060052325 - Utilization of non-viral sequences for minus-strand dna transfer and gene reconstitution A retroviral vector for gene reconstitution is provided that includes a 3′ portion of a heterologous nucleic acid sequence 5′ of a first att site of the retroviral vector, a 5′ portion of the heterologous nucleic acid sequence 3′ of a second att site of the retroviral vector. In this ... 03/09/06 - 20060052324 - Methods and compositions for cell activation Methods and compositions for activating a cell are provided. In practicing the subject methods, a cell including a coding sequence for either a telomerase reverse transcriptase (TERT) or a telomerase RNA component (TERC) is activated by conditionally increasing expression of the coding sequence. Also provided are transgenic animals and systems ... 03/09/06 - 20060052323 - Method to inhibit cell growth using oligonucleotides Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or ... 03/09/06 - 20060052322 - Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers ... 03/09/06 - 20060052321 - Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The ... 03/09/06 - 20060052320 - Mammalian genes involved in rapamycin resistance and tumorgenesis annexin xiii genes The present invention provides methods and compositions for regulating rapamycin resistance and/or tumorgenesis by modulating the expression and/or the activity of annexin XIII gene. The invention also provides methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression and/or activity of annexin XIII gene. The invention also ... 03/09/06 - 20060052319 - Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes This invention relates to the fields of molecular biology and oncology. More particularly, this invention relates to the sensitization of cancerous cells to therapeutic agents. The invention provides methods, compositions, and formulations for potentiating or enhancing the toxicity of various cytotoxins and oxidizing agents, and of reducing the resistance and ... 03/02/06 - 20060046971 - Treatment of transformed or infected biological cells The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method ... 02/23/06 - 20060040886 - Compositions and methods for treatment of prostate and other cancers Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for ... 02/23/06 - 20060040885 - Bioprosthetic heart valves The invention provides methods and materials related to heart valves and the treatment of valvular heart disease. Specifically, the invention provides non-murine heart valve cells and heart valve cusps as well as methods for making heart valves. The invention also provides methods and materials for (1) slowing heart valve degeneration, ... 02/23/06 - 20060040884 - Antisense oligonucleotides directed to genes regulated by trapoxin-induced hdac inhibition Antisense compounds, compositions and methods are provided for modulating the expression of trapoxin A regulated genes, including but not limited to those genes induced by ectopic expression of p21waf1 that are disclosed herein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding these genes. Methods of ... 02/23/06 - 20060040883 - Methods for treating cancer using anti-wnt2 monoclonal antibodies and sirna This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that overexpress Wnt2. The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such ... 02/23/06 - 20060040882 - Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference ... 02/23/06 - 20060040881 - Modulators of coagulation factors The invention provides improved nucleic acid ligands that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass. ... 02/23/06 - 20060040880 - Methods and compositions for treating neuropathic pain Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention ... 02/23/06 - 20060040879 - Chloroquine coupled nucleic acids and methods for their synthesis This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount ... 02/23/06 - 20060040878 - Bacterial antigen induced bone morphogenesis Bone growth following a spinal fusion procedure is enhanced by packing the fusion site with a mixture of a bone material such as allograft or autograft, and an antigen produced from bacteria or parasitic organisms. A composition for inducing bone morphogenesis also is disclosed. ... 02/16/06 - 20060035859 - Treating severe and acute viral infections Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA. Avian influenza is treated with natural human alpha interferon, neuraminidase inhibitor(s) and ribavirin. Effects of influenza virus are mitigated with a dsRNA in combination with a neuraminidase ... 02/16/06 - 20060035858 - Methods for modulating lipoprotein and cholesterol levels in humans Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided. ... 02/16/06 - 20060035857 - Methods and compositions for the diagnosis and treatment of cancer Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities. ... 02/16/06 - 20060035856 - Purified polypeptides having il-13 receptor activity This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and/or IL13 receptor β and uses thereof. ... 02/16/06 - 20060035855 - Purified polypeptides having il-13 receptor activity This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4. ... 02/16/06 - 20060035854 - Compositions and methods for coating medical devices The present invention provides compositions and methods for coating medical devices with pharmaceutical agents and devices coated with the compositions. The coated devices provide controlled or sustained release of pharmaceutical agents for the treatment of wounds or disease. ... 02/16/06 - 20060035853 - Methods for tailoring the immune response to an antigen or immunogen The invention relates to methods and reagents for immunizing animals to elicit specific cellular and humoral immune-responses against specific antigens, such as viral antigens, including HBsAg antigen. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses ... 02/16/06 - 20060035852 - Genetic products differentially expressed in tumors and the use thereof The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. Said invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which ... 02/16/06 - 20060035851 - Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair It is described a composition comprising an effective amount of the HMGBl protein or functional parts thereof, of HMGBl expressing vectors, for the treatment of tissue damage and/or to promote tissue repair and regeneration. It is further described a composition comprising an effective amount of an antagonist of the HMGBl ... 02/16/06 - 20060035850 - Plant thymidine kinases and their use This invention relates to novel plant thymidine kinases and their use in gene therapy. More specifically the invention provides novel thymidine kinases derived from tomato, pine, rice or thale cress. In further aspects the invention provides novel polynucleotides encoding the plant thymidine kinases, vector constructs comprising the polynucleotide, host cells ... 02/16/06 - 20060035849 - Methods and composition for modulating type i muscle formation using pgc-1 alpha The invention provides novel methods and compositions for modulating type I muscle formation through modulation of PGC-1α activity or expression. Also provided are methods for identifying compounds that modulate type I muscle formation through modulation of PGC-1α activity or expression. Further provided are methods for treating disorders associated with type ... 02/09/06 - 20060030541 - Genes involved in osteogenesis, and methods of use The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or ... 02/09/06 - 20060030540 - Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent The present invention is directed toward a method of producing transgenic animals by administration of a composition to an animal via a natural gastrointestinal pathway. The composition achieves widespread distribution, systemic expression and sustained delivery in the animal. More particularly, the invention discloses a method for producing a transgenic animal ... 02/09/06 - 20060030539 - Product and process for inhibition of biofilm development Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing ... 02/09/06 - 20060030538 - Methods for reducing or preventing localized fibrosis using sirna Methods for reducing or preventing localized fibrosis in a localized tissue region using SiRNA technology. ... 02/09/06 - 20060030537 - Ceramide kinase and uses thereof The invention relates to a method of inhibiting the production of ceramide-1-phosphate in a cell by delivering to the cell a ceramide kinase antagonist. The invention also relates to a method of treating a condition related to activation of phospholipase A2 in a subject by administering to the subject a ... 02/09/06 - 20060030536 - Combination therapies for cancer and proliferative angiopathies Compositions and methods for treating cancer and proliferative angiopathies are provided. A composition can include an inhibitor of the Jak2/Stat3 signaling pathway and an inhibitor of the PI3k/Akt signaling pathway. In certain cases, the two inhibitors are capable of acting synergistically as compared to either inhibitor alone. ... 02/09/06 - 20060030535 - Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics Materials and methods are provided to modulate, in a controlled manner, the pharmacokinetic and biodistribution properties of nucleic acid aptamers, and to enhance their safety and efficacy properties as therapeutic agents. ... 02/09/06 - 20060030534 - Treatment of neurological disorders by dsrna administration The present invention relates to methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein said dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment. ... 02/02/06 - 20060025374 - Novel oligoribonucleotide derivatives for specific inhibition of gene expression The present invention relates to oligoribonucleotide derivatives which have a 2′5′-linked oligoribonucleotide residue without a 5′-phosphate residue on the 3′ end and to the use thereof for specific inhibition of gene expression. ... 02/02/06 - 20060025373 - Modulation of glucocorticoid receptor expression Compounds, compositions and methods are provided for modulating the expression of glucocorticoid receptor. The compositions comprise oligonucleotides, targeted to nucleic acid encoding glucocorticoid receptor. Methods of using these compounds for modulation of glucocorticoid receptor expression and for diagnosis and treatment of diseases and conditions associated with expression of glucocorticoid receptor ... 02/02/06 - 20060025372 - Antisense modulation of ptp1b expression Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided. ... 02/02/06 - 20060025371 - Methods of inhibiting cox-2 The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for COX-2, and further provides methods of reducing expression of COX-2 in cells (e.g., cancer cells). ... 02/02/06 - 20060025370 - Methods of inhibiting vegf-c The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for VEGF-C, and further provides methods of reducing expression of VEGF-C in cells (e.g., cancer cells). ... 02/02/06 - 20060025369 - Methods of inhibiting manganese-containing superoxide dismutase 2 (mnsod) The present invention provides RNA molecules (e.g., antisense, RNAi, or siRNA) specific for MnSOD, and further provides methods of reducing expression of MnSOD in cells (e.g., cancer cells). ... 02/02/06 - 20060025368 - Growth hormone releasing hormone enhances vaccination response This invention discloses compositions and methods of: vaccinating a subject; enhancing the vaccination efficiency; preparing a subject prior to vaccination response; and improving the clinical outcome after infectious challenge in a subject that has been vaccinated. More specifically, the invention pertains to delivering into a tissue of the subject a ... 02/02/06 - 20060025367 - Adenovirus vectors encoding brain natriuretic peptide The invention provides isolated and purified nucleic acid molecules encoding a natriuretic peptide useful in methods to inhibit or prevent heart failure. ... 02/02/06 - 20060025366 - Immunostimulatory sirna molecules and uses therefor The present invention provides siRNA molecules and methods of using such siRNA molecules to modulate an immune response and to silence expression of a target gene. ... 02/02/06 - 20060025365 - Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... 02/02/06 - 20060025364 - Regulation of peritoneal healing and adhesion development Methods for the prevention of adhesion formation and development, and for the stimulation of fibrosis, involve the administration of therapeutic formulations to a patient containing inhibitors or stimulators to selected molecular adhesion markers. The molecular markers of the invention include Caspase 2, Caspase 3, Caspase 9, PPARα, PPARβ, PPARγ1, PPARγ2, ... 02/02/06 - 20060025363 - Use of antisense oligonucleotides for the treatment of degenerative skin conditions A pharmaceutical or cosmetic composition for topical application containing one or more oligonucleotides which are capable of hybridizing with a mRNA or a gene sequence which codes for a connective-tissue decomposing enzyme, or a physiologically compatible salt thereof. The compositions are suitable in particular for the treatment of degenerative skin ... 02/02/06 - 20060025362 - Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation The present invention relates to a recombinant protein consisting of Guanylate Binding Protein-1 (GBP-1), or one or more functional parts thereof, linked to a shuttle protein. The present invention also relates to an expression vector comprising the Guanylate Binding Protein 1 (GBP-1) gene or parts thereof. The introduction of said ... 02/02/06 - 20060025361 - Rna interference mediated inhibition of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression ... 02/02/06 - 20060025360 - Human cervical cancer protooncogene and protein encoded therein A human cervical cancer 1 protooncogene having a base sequence of SEQ ID:1 or a fragment thereof is overexpressed in various cancer tissues and can be used in diagnosing various cancers and an anti-sense gene complementary thereto can be used in treating cancers. ... 01/26/06 - 20060019924 - Novel mrna splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy The present invention relates to novel nucleic acid and protein molecules and their use in neuroblastoma therapy and diagnosis. ... 01/26/06 - 20060019923 - Methods and compositions for inducing innate immune responses The invention relates to TLR ligand formulations that comprise immune stimulating complexes and their use in inducing innate immunity. ... 01/26/06 - 20060019922 - Selective killing of cancerous cells The presently disclosed subject matter provides methods for selectively conferring toxicity on cancerous cells. Also provided are systems and kits that can be employed for performing the disclosed method. ... 01/26/06 - 20060019921 - Nucleic acid adjuvants Recombinant nucleic acid molecules are described. The molecules have two nucleic acid sequences, wherein the first nucleic acid sequence is a truncated A subunit coding region obtained or derived from a bacterial ADP-ribosylating exotoxin, and the second nucleic acid sequence is a truncated B subunit coding region. Vectors and compositions ... 01/26/06 - 20060019920 - Antisense modulation of mekk4 expression Antisense compounds, compositions and methods are provided for modulating the expression of MEKK4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK4. Methods of using these compounds for modulation of MEKK4 expression and for treatment of diseases associated with expression of MEKK4 are provided. ... 01/26/06 - 20060019919 - Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... 01/26/06 - 20060019918 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of ... 01/26/06 - 20060019917 - Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina) The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of stromal cell-derived factor-1 (SDF-1) gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and ... 01/26/06 - 20060019916 - Immunostimulatory nucleic acids for inducing il-10 responses The invention relates to methods and products for inducing IL-10 expression using immunostimulatory nucleic acids. In particular, the invention relates to methods and products for inducing IL-10 expression without inducing high levels of IFN-α expression. IL-10-inducing immunostimulatory nucleic acids preferably include a TC dinucleotide at the 5′ end and a ... 01/26/06 - 20060019915 - Method to modulate the immune system with a novel guanine nucleotide exchange factor The present invention provides a method of modulating T cell receptor (“TCR”) dependant regulation of a signaling factor in a T cell, and a method of modulating the proliferation and/or differentiation of a T cell, which includes administering to the T cell an IBP modulator in an amount effective to ... 01/26/06 - 20060019914 - Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes The presently disclosed subject matter provides DNA molecules designed to down regulate the expression of MMP genes in a cell. Also provided are compositions comprising the DNA molecules. The presently disclosed subject matter further provides methods of using the DNA molecules to inhibit metastasis of a cancer cell. The presently ... 01/26/06 - 20060019913 - Rna interference mediated inhibtion of protein tyrosine phosphatase-1b (ptp-1b) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PTP-1B gene expression ... 01/26/06 - 20060019912 - Cell transfecting formulations of small interfering rna related compositions and methods of making and use Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions. ... 01/26/06 - 20060019911 - Drug-carrier complexes and methods of use thereof Drug-carrier complexes, drug carriers, pharmaceutical formulations, methods of delivery drugs to an organism or tissue culture, methods of increasing the solubility of a substance, targeted carriers, drug delivery systems and implants are described. The compositions and methods of the invention include forming complexes having reversible associations between nucleotides and drugs. ... 01/26/06 - 20060019910 - Methods for treating and preventing insulin resistance and related disorders The invention provides methods, therapeutics and kits for treating and preventing diseases or conditions associated with excessive lipolysis, in particular TNF-α induced lipolysis, and/or excessive free fatty acid levels. Exemplary conditions include insulin-resistance, diabetes, in particular NIDDM, obesity, glucose intolerance, hyperinsulinemia, polycystic ovary syndrome, and coronary artery disease. In a ... 01/26/06 - 20060019909 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked ... 01/19/06 - 20060014715 - Control of gene expression The present invention relates generally to a method of modifying gene expression and to synthetic genes for modifying endo gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the invention utilises recombinant DNA technology to post-transcriptionally modify or ... 01/19/06 - 20060014714 - Genetic induction of anti-viral immune response and genetic vaccine for viruses An approach to genetic vaccine methodology is described. A genetic construction encoding antigenic determinants of a virus is transfected into cells of the vaccinated individuals using a particle acceleration protocol so as to express the viral antigens in healthy cells to produce an immune response to those antigens. ... 01/19/06 - 20060014713 - Immunostimulatory oligonucleotide multimers The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary. ... 01/19/06 - 20060014712 - Controlled delivery of therapeutic compounds The present invention provides compositions for the controlled delivery of compounds into cells. Entry of the compound into a cell is mediated by a cell penetrating peptide capable of translocating the compound across a cell membrane. An inhibitor of cell penetrating peptide, which activity is regulatable by action of a ... 01/19/06 - 20060014711 - Methods for modulating expression of exogenous genes in mammalian systems, and products related thereto In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in a mammalian subject employing modified ecdysone receptors. Also provided are modified ecdysone receptors, as well as homomeric and heterodimeric receptors containing sane, nucleic acids encoding invention modified ecdysone receptors, modified ... 01/19/06 - 20060014710 - Immunization of infants The present invention relates to methods and compositions which may be used to immunize infant mammals against a target antigen, wherein an immunogenically effective amount of a nucleic acid encoding a relevant epitope of a desired target antigen is administered to the infant. It is based, at least in part, ... 01/12/06 - 20060009412 - Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src The present invention describes methods for modulating angiogenesis in tissues using Src protein, modified Src protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Src protein, or nucleic acids encoding therefor, or for potentiating angiogenesis using an active Src protein, or ... 01/12/06 - 20060009411 - Targeting compounds to a cell nucleus We disclose gene delivery systems that target exogenous nucleic acids to the nucleus of mammalian cells and are delivered to chromatin during cellular mitosis, remaining within the nucleus after mitosis. ... 01/12/06 - 20060009410 - Effects of apolipoprotein b inhibition on gene expression profiles in animals Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese ... 01/12/06 - 20060009409 - Double-stranded oligonucleotides Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the ... 01/12/06 - 20060009408 - Sirna-mediated gene silencing with viral vectors The present invention is directed to viral vectors encoding small interfering RNA molecules (siRNA) targeted against a gene of interest, and methods of using these viral vectors. ... 01/12/06 - 20060009407 - Enhancement of vascular function by modulation of endogenous nitric oxide production or activity Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term ... 01/12/06 - 20060009406 - Vectors having both isoforms of beta-hexosaminidase Disclosed are compositions and methods related to nucleic acid constructs containing a HexB encoding element and a HexA encoding element. These constructs can be used in the treatment of Tay-Sachs and Sandoff disease. ... 01/12/06 - 20060009405 - Bispecific oligonucleotide for the treatment of cns malignancies CNS malignancy is treated in a subject suffering from a CNS malignancy by administering to the subject an antisense oligonucleotide having a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is of sufficient length to act as ... 01/12/06 - 20060009404 - Tumor ablation in combination with pharmaceutical compositions Therapeutic methods, compositions, and apparatus are provided for the treatment and ablation of body masses, such as tumors. RF treatment is combined with pharmaceutical compositions so that tumor masses are ablated and therapeutically effective compositions and doses that include or produce p53 tumor suppressor or peptides and variants thereof are ... 01/12/06 - 20060009403 - Dna demethylase antisense and chemotherapy combination The invention concerns a combination product comprising an antisense oligonucleotide of the gene encoding MBD2-demethylase and at least an agent used in antitumour chemotherapy, in particular bleomycin, for simultaneous, separate or prolonged use for treating proliferative and inflammatory diseases, in particular for cancer treatment. ... 01/12/06 - 20060009402 - In vivo production of small interfering rnas that mediate gene silencing The invention provides engineered RNA precursors that when expressed in a cell are processed by the cell to produce targeted small interfering RNAs (siRNAs) that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference (RNAi) pathway. By introducing nucleic acid molecules that encode these engineered ... 01/05/06 - 20060003962 - Methods and products related to treatment and prevention of hepatitis c virus infection The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone. ... 01/05/06 - 20060003961 - Negative regulation of hypoxia inducible factor 1 by os-9 The present invention discloses that OS-9 interacts with both HIF-1a and HIF-1a prolyl hydroxylases. Overexpression of OS-9 promotes the hydroxylation of HIF-1a, HIF-1a binding to VHL, proteasomal degradation of HIF-1a, and loss of HIF-1-mediated transcription. OS-9 loss-of-function increases HIF-1a protein levels and HIF-1-mediated transcription under non-hypoxic conditions. These data indicate ... 01/05/06 - 20060003960 - Tumor treatment The invention concerns an improved method for treating tumor, including cancer, which combines the administration of a chemotherapeutic agent and an antagonist of a gene product the expression of which is upregulated by the chemotherapeutic agent. The invention further concerns methods and means for the diagnosis and classification of tumors, ... 01/05/06 - 20060003959 - Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same The present invention relates to methods for stimulating muscle growth and/or for inhibiting muscle atrophy in a subject suffering from or predisposed to having a muscle wasting disease by administering an agent that increases the expression of the runx1 gene or gene product in an individual. The invention further provides ... 01/05/06 - 20060003958 - Novel polynucleotides related to oligonucleotide arrays to monitor gene expression The present invention provides an oligonucleotide array capable of identifying genes and related pathways involved with the induction of a particular phenotype by a cell line, e.g., the genes and related pathways involved with the induction of transgene expression by the cell line. The invention is particularly useful when there ... 01/05/06 - 20060003957 - Rna virus expression and replication, methods and uses therefor A norovirus-permissive cell culture infected with a norovirus, and methods of culturing a norovirus, are disclosed. Norovirus-permissive cells include dendritic cell-lineage cells, and macrophage-lineage cells, such as dendritic cells, and macrophages having a deficiency in a cellular anti-viral pathway such as a STAT-1-dependent pathway, an interferon receptor-dependent pathway, or a ... 01/05/06 - 20060003956 - Materials and methods for the derepression of the e-cadherin promoter Nucleic acid is provided that is capable, when suitably introduced into or expressed within a mammalian cell that otherwise expresses the transcription factor Snail, of suppressing Snail expression by RNAi. Preferred target sequences of Snail mRNA are gatgcacatccgaagccac (SEQ ID NO:1) and sequences overlapping therewith. Snail expression is associated with ... 01/05/06 - 20060003955 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 01/05/06 - 20060003954 - Therapy inhalation involving antisense oligonucleotides for treating idiopathic pulmonary fibrosis The invention provides antisense DNA oligonucleotides which are effective in inhibiting the expression of a wild type COL1A1 gene, wherein said oligonucleotides are used in inhalation therapy to treat various lung diseases. ... 01/05/06 - 20060003953 - Compositions and their uses directed to bone growth modulators Disclosed herein are compounds, compositions and methods for modulating the expression of a bone growth modulator in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. ... 01/05/06 - 20060003952 - Oligomeric compounds having modified phosphate groups Oligomeric compounds having at least one phosphorothioate monoester are provided having increased nuclease resistance and binding affinity to a complementary strand of nucleic acid. Such oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and ... 12/29/05 - 20050288248 - Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders. ... 12/29/05 - 20050288247 - Inducible inactivation of synaptic transmission The invention provides molecular systems for inducible and reversible inactivation of synaptic transmission. These systems can be used for studying neuronal networks and for treating conditions involving abnormally high neuronal activity or excitotoxic damage. ... 12/29/05 - 20050288246 - Peptide conjugated, inosine-substituted antisense oligomer compound and method A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which ... 12/29/05 - 20050288245 - Methods and compositions for reducing viral genome amounts in a target cell Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target ... 12/29/05 - 20050288244 - Oligonucleotides comprising a c5-modified pyrimidine One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a ... 12/29/05 - 20050288243 - Methods and compositions for treating gain-of-function disorders using rna interference The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi ... 12/29/05 - 20050288242 - Rna interference mediated inhibition of ras gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating RAS, e.g. K-RAS, H-RAS, and/or N-RAS gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RAS, ... 12/29/05 - 20050288241 - Novel polypeptides and nucleic acids encoded thereby Disclosed are novel polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same. ... 12/22/05 - 20050282767 - Inhibitors of epoxide hydrolases for the treatment of hypertension wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1—R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur ... 12/22/05 - 20050282766 - Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, ... 12/22/05 - 20050282765 - Enzyme having s-adenosyl-l-homocysteine hydrolase (ahcy) type activity Enzyme having AHCY-type activity and DNA sequences which encode the enzyme. The enzyme is useful in a screening assay to identify compounds useful as immunosuppression agents. ... 12/22/05 - 20050282764 - Method of identifying nucleic acid compositions for muting expression of a gene The invention provides compositions and methods for muting expression of an endogenous gene in an animal cell, the muting resulting from providing a muting nucleic acid to a cell. The muting nucleic acid comprises a transgene, which is substantially homologous to a portion of the endogenous gene. The portion of ... 12/22/05 - 20050282763 - Methods of treating bladder disorders Methods of treating bladder disorders, including bladder cancer and inflammatory bladder diseases such as interstitial cystitis are disclosed. The methods include identifying a mammal that has or is at risk for having a bladder disorder and administering isolated nucleic acid sequences to the mammal. Nucleic acids used in the methods ... 12/22/05 - 20050282762 - Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present ... 12/22/05 - 20050282761 - Modulation of growth hormone receptor expression and insulin-like growth factor expression Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of ... 12/22/05 - 20050282760 - Antisense modulation of ptpn12 expression Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided. ... 12/15/05 - 20050277613 - Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations ... 12/15/05 - 20050277612 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a SPHK polypeptide, or fragment thereof, and measuring a compound-SPHK property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including phosphorylated kinase substrate and/or amyloid ... 12/15/05 - 20050277611 - Cationic cardiolipin analoges and its use thereof The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, pharmaceutical compositions comprising cationic cardiolipin analogs, and methods of using such liposomes and compositions, in delivering active pharmaceutical agents to treat ... 12/15/05 - 20050277610 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that ... 12/15/05 - 20050277609 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 12/15/05 - 20050277608 - Rna interference mediated inhibtion of vitamin d receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating Vitamin D Receptor (VDR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Vitamin D Receptor ... 12/15/05 - 20050277607 - Compositions and methods for regulating peptidyltransferase activity and uses thereof The present invention provides compositions and means to identify compositions that increase −1 PRF programmed ribosomal frameshift (−1PRF) efficiencies and/or decrease peptidyltransferase activity in a cell, and thus directly affect viral replication or assembly of viral particles. Compositions identified in accordance with the invention specifically inhibit the interaction between ribosomal ... 12/15/05 - 20050277606 - Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1 A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid ... 12/15/05 - 20050277605 - Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and/or (b) promotes development or activity of antigen ... 12/15/05 - 20050277604 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 12/15/05 - 20050277603 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such ... 12/08/05 - 20050272685 - Intraductal treatment targeting methylated promoters in breast cancer The invention provides compositions for targeting methylated promoters in breast cancer and pre-cancer patients. The invention also provides methods for intraductal treatment of breast cancer and pre-cancer patients by delivering intraductally an agent that targets methylated promosters of silenced genes. ... 12/08/05 - 20050272684 - Breast cancer resistance protein (bcrp) and the dna which encodes it The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs. ... 12/08/05 - 20050272683 - Antisense oligonucleotides against thymidylate synthase Antisene oligonucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligonucleotides targeted to sequences in the 3′ end of TS mRNA, which are both cytostatic on their own when administered to human tumour cell lines, and which also enhance the toxicity of anticancer ... 12/08/05 - 20050272682 - Sirna targeting pi3k signal transduction pathway and sirna-based therapy Small interfering RNAs (siRNAs) are provided specifically targeting a PI3K signal transduction pathway. Also provided are various siRNA-based therapies. ... 12/08/05 - 20050272681 - Ribosome structure and protein synthesis inhibitors The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and ... 12/08/05 - 20050272680 - Modulation of diacylglycerol acyltransferase 2 expression Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression ... 12/08/05 - 20050272679 - Modified polynucleotides and uses thereof Provided is a polynucleotide comprising mRNA, rRNA or viral RNA, comprising ribose rings that are covalently modified at the 2′-OH position. Further provided are methods for producing a double-stranded oligo- or polynucleotide from a template comprising an oligo- or polyribonucleotide, a proportion of the ribose rings of which are covalently ... 12/08/05 - 20050272678 - Bmp-6 estrogen responsive element and methods of use thereof This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack ... 12/08/05 - 20050272677 - Delivery of a substance to a pre-determined site The invention is directed to delivery vehicles for delivering a substance of interest to a predetermined site. The delivery vehicle includes a substance and means for inducing availability of at least one compartment of the delivery vehicle toward the exterior, thus, allowing access of the substance to the exterior of ... 12/01/05 - 20050267065 - Modulation of aurora b expression Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B ... 12/01/05 - 20050267064 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 12/01/05 - 20050267063 - Antisense modulation of p70 s6 kinase expression Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with ... 12/01/05 - 20050267062 - Regulation of angiogenesis with zinc finger proteins Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by ... 12/01/05 - 20050267061 - Methods and compositions for treating neuropathic and neurodegenerative conditions Disclosed herein are engineered zinc finger proteins which modulate transcription of the gene encoding vascular endothelial growth factor-A (VEGF-A) and other genes encoding products with neurotrophic activities. Also disclosed are methods for the use of these engineered zinc finger proteins in the treatment of neuropathy (including diabetic neuropathy), and other ... 12/01/05 - 20050267060 - Combinatorial methods and compositions for treatment of melanoma The present invention provides a rational basis for combining targeted therapies together with selected chemotherapeutics, which does not currently exist for the treatment of melanoma. The present invention is based on the present inventors' discovery that Akt3 regulates apoptosis and V599E B-Raf regulates growth and vascular development in melanoma. Inventors ... 12/01/05 - 20050267059 - Syk-targeted nucleic acid interference The present invention provides methods and compositions for attenuating expression of Spleen Tyrosine Kinase, Syk. In general, the described methodology involves the use of RNAi constructs that are targeted to a Syk mRNA sequence. ... 12/01/05 - 20050267058 - Rna interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and/or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity ... 12/01/05 - 20050267057 - Immunostimulatory nucleic acid molecules Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant. ... 11/24/05 - 20050261235 - 2' ,5' -oligoadenylate analogs wherein m is 0 or 1; n is 0 to 2; R1 represents an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to ... 11/24/05 - 20050261234 - Gfap-based gene therapy for treatment of retinal diseases Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid ... 11/24/05 - 20050261233 - Modulation of glucose-6-phosphatase translocase expression Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders. ... 11/24/05 - 20050261232 - Non-natural ribonuclease conjugates as cytotoxic agents The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such ... 11/24/05 - 20050261231 - Hepatocyte growth factor nucleic acid sequence to enhance musculocutaneous flap survival The present invention relates to the use of growth factors in improving tissue survival. In particular, the invention describes methods for enhancing organ transplant, musculocutaneous flap or skin graft survival by administering a nucleic acid sequence encoding hepatocyte growth factor. ... 11/24/05 - 20050261230 - Method for the prophylaxis and/or treatment of medical disorders The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on ... 11/24/05 - 20050261229 - Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the ... 11/24/05 - 20050261228 - Antisense modulation of interleukin 12 p35 subunit expression Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment ... 11/24/05 - 20050261227 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, ... 11/24/05 - 20050261226 - Methods and compositions for the treatment of cancer with oligonucleotides directed against egr-1 Oligonuclotides, compositions and methods for modulating the over-expression of EGR-1 in cancer cells. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Egr-1. Methods include using these compounds for modulation of Egr-1 expression in cancer cells in which Egr-1 is over-expressed for the treatment of cancer. ... 11/24/05 - 20050261225 - Peptides that deliver antisense oligonucleotides which downregulate protein expression in cells The present invention provides a peptide that can complex with an oligonucleotide, e.g. an antisense oligonucleotide, and deliver it into a cell. The present invention also provides compositions comprising a complex of such a peptide and an oligonucleotide and methods of delivering an oligonucleotide into a cell and of inhibiting ... 11/24/05 - 20050261224 - Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not ... 11/24/05 - 20050261223 - Rip140 regulation of glucose transport Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat. ... 11/24/05 - 20050261222 - Oligoribonucleotides for the treatment of irritative or inflammatory skin symptoms through rna interference The invention is a double-stranded oligoribonucleotide or a physiologically compatible salt thereof, which is capable of inducing the degradation of mRNA of one of more structures involved in inflammation or irritation of the skin. The invention is also cosmetic or therapeutic compositions comprising one or more such double-stranded oligoribonucleotide and ... 11/24/05 - 20050261221 - Compositions and methods for enhanced delivery of compounds via transfection complexes The present invention relates to compositions and methods for enhanced delivery of compounds (e.g., drugs, nucleic acids, peptides, etc.) via transfection complexes (e.g., liposomes). In particular, the present invention utilizes agents that synergistically enhance the ability of a transfection complex to deliver a compound to cells or tissue. ... 11/24/05 - 20050261220 - Tumor treating combinations, compositions and methods The invention relates to compositions and methods of use in the treatment of tumors in animals. The invention is particularly concerned with the combination of HIF inhibiting agents, specifically antisense HIF-1, with antiangiogenic agents. ... 11/24/05 - 20050261219 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin ... 11/24/05 - 20050261218 - Oligomeric compounds and compositions for use in modulation small non-coding rnas Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment ... 11/24/05 - 20050261217 - Modulation of pumilio 1 expression Compounds, compositions and methods are provided for modulating the expression of Pumilio 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Pumilio 1. Methods of using these compounds for modulation of Pumilio 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Pumilio 1 ... 11/24/05 - 20050261216 - Modulation of nanos 1 expression Compounds, compositions and methods are provided for modulating the expression of Nanos 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Nanos 1. Methods of using these compounds for modulation of Nanos 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Nanos 1 ... 11/24/05 - 20050261215 - Methods and immune modulatory nucleic acid compositions for preventing and treating disease This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly ... 11/24/05 - 20050261214 - Complexes for transferring substances of interest into a cell The present invention concerns new polar compounds, complexes and compositions comprising them, wherein said compound comprises: (i) a polar headgroup spacer, (ii) at least one hydrophobic moiety, and (iii) at least one hydrophilic polymer, and wherein said polar headgroup spacer is coupled to said hydrophobic moiety and to said hydrophilic ... 11/24/05 - 20050261213 - Nucleic acid compositions and methods for use Polynucleotide compositions encoding a tumor antigen antigenic determinant and optionally including a nucleic acid adjuvant are disclosed. The compositions are useful for prophylaxis or treatment of cancer. ... 11/24/05 - 20050261212 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering rna The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with Alzheimer's disease. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against NOGO ... 11/17/05 - 20050256077 - Gastrointestinal stem cells and uses thereof The present invention relates to compositions and methods concerning isolated gastrointestinal stem cells. Particularly, the invention provides isolated gastrointestinal stem cells comprising a CD45 negative marker, a collagen IV negative marker, and that is Msi-1 positive. In particular embodiments the isolated cells are comprised in a single cell suspension. In ... 11/17/05 - 20050256076 - Rna interference modulators of hedgehog signaling and uses thereof The instant application relates to methods and reagents for modulating the Hedgehog signaling pathway using RNA interference technology (RNAi). The application provides potential targets of the Hedgehog RNAi, methods to identify additional Hedgehog signaling pathway components, methods to inhibit Hedgehog signaling targets using siRNA, and their uses in the treatment ... 11/17/05 - 20050256075 - Use of vegf-c or vegf-d gene or protein to prevent restenosis The present invention provides materials and methods for preventing stenosis or restenosis of a blood vessel using Vascular Endothelial Growth Factor C (VEGF-C) and/or Vascular Endothelial Growth Factor D (VEGF-D) genes or proteins. ... 11/17/05 - 20050256074 - Methods and compositions for regulating lymphocyte activity The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention provides a method to promote T lymphocyte development using low dose Hedghog, and a method to inhibit T lumphocyte development using high dose ... 11/17/05 - 20050256073 - Immunostimulatory viral rna oligonucleotides Immunostimulatory sequence-specific RNA oligonucleotides corresponding to 3′ terminal sequences of single-stranded minus-sense RNA genomic RNAs are provided. Also provided are compositions and methods relating to an immunostimulatory 4-mer RNA motif provided as 5′-C/U-U-G/U-U-3′. Incorporation of this short RNA motif is sufficient to confer new and altered immunostimulatory properties in new ... 11/17/05 - 20050256072 - Dual functional oligonucleotides for use in repressing mutant gene expression The present invention is based, in part, on the discovery that endogenous mRNAs can be recruited for translational repression of target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means by which to treat genetic (e.g., genetic neurodegenerative diseases such as Huntington's Disease) or non-genetic diseases ... 11/17/05 - 20050256071 - Inhibitor nucleic acids The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an ... 11/17/05 - 20050256070 - Adjuvant The present invention relates to the fields of vaccines, vaccine adjuvants, molecular biology and immunology, and generally adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies employing such compositions. The invention in particular relates to DNA ... 11/17/05 - 20050256069 - Irna agents with biocleavable tethers The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose that further includes a tether having one or more linking groups, in which at least one of the linking groups is a cleavable linking group. ... 11/17/05 - 20050256068 - Rna interference mediated inhibition of stearoyl-coa desaturase (scd) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating Stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Stearoyl-CoA desaturase (SCD) gene ... 11/17/05 - 20050256067 - Method of preparing a treatment product, treatment product and a plasmid construct The method of the invention for preparing a treatment product is characterized by using a starting plasmid based on a virus belonging to the Togaviridae stock from which the genes encoding capsid proteins of the virus have been deleted. An RNA encoding virus-like particles (VLP-RNA) is prepared by manipulating the ... 11/10/05 - 20050250727 - Use of immunomodulating agents Pharmaceutical compositions useful for treating immunosuppressive disease and containing compounds capable of inhibiting cAMP-dependent protein kinase A (PKA) as well as use of the same, are described. ... 11/10/05 - 20050250726 - Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases The invention provides methods and compositions for using immunostimulatory nucleic acids to treat non-allergic inflammatory diseases. Non-allergic inflammatory diseases that may be treated according to the methods and products of the invention include psoriasis and inflammatory bowel disease. The invention further provides methods for augmenting a Th1 response to immunostimulatory ... 11/10/05 - 20050250725 - Regulation of the p21 gene and uses thereof The present invention in general is directed to methods for manipulating cyclin-dependent kinase inhibitor activity. Such manipulation will reduce or eliminate the expression of p21 gene based on specific requirements. This will be helpful in treating or preventing pathophysiological state in an individual which is characterized by undesirable level of ... 11/10/05 - 20050250724 - Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death Provided herein are methods relating to inhibition of PUMA function for preventing or reducing myocardial cell death. A method for preventing or reducing ischemia/reperfusion induced myocardial cell death in a human is provided as are methods for identifying pharmaceuticals which interfere with PUMA function. Also herein provided is a method ... 11/10/05 - 20050250723 - Immunostimulation by chemically modified rna The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed ... 11/10/05 - 20050250722 - Fcgammariia-specific nucleic acid interference The present invention provides methods and compositions for attenuating expression of FcγRIIA. In general, the described methodology involves the use of RNAi constructs that are targeted to a FcγRIIA mRNA sequence. ... 11/10/05 - 20050250721 - Gene therapy for congestive heart failure The present invention relates to methods and compositions for enhancing cardiac function in mammalian hearts by inserting transgenes that increase beta-adrenergic responsiveness within the myocardium. The present invention can thus be used in the treatment of heart disease, especially congestive heart failure. ... 11/10/05 - 20050250720 - Novel compound A method for the provision of an appetite control agent which method comprises using one or more agonists or antagonists of a GPR19 receptor as test compounds in one or more appetite control test procedures, and selecting an active compound for use as an appetite control agent. ... 11/10/05 - 20050250719 - Inhibition of protein kinase c alpha for treatment of diabetes mellitus and cardiovascular diseases The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-α), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy. ... 11/10/05 - 20050250718 - Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity The present invention provides pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity. By attaching a compound to a minus-strand RNA virus envelope protein having hemagglutinating activity, a pharmaceutical- or gene-carrier composition with lower hemagglutinating activity than a composition to which the compound has not been attached can be successfully constructed. ... 11/10/05 - 20050250717 - Chromatin remodeling protein as a marker expressed by stromal progenitor cells The present invention provides a chromatin remodeling protein, designated ChroM as well as alternatively spliced variants, which serves as markers for stromal precursor cells and osteogenic and muscle progenitor cells. This ChroM marker was found to be present in proliferating progenitor cells but is either absent or not predominantly present ... 11/10/05 - 20050250716 - Immunostimulatory oligodeoxynucleotides The invention relates to the use of inununostimulatory deoxyinosine/deoxyuridine containing oligodeoxynucleotides for pharmaceutical application, such as treating and preventing chronic infectious diseases, acute decrements in air flow, parasitic infections and the like. ... 11/03/05 - 20050245477 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 11/03/05 - 20050245476 - Treatment of neuropathic pain with zinc finger proteins A variety of zinc finger proteins (ZFPs) and methods utilizing such proteins are provided for use in treating neuropathic pain. ZFPs that bind to a target site in genes that are aberrantly expressed in subjects having neuropathic pain are described. In addition, ZFPs that bind to a target site in ... 11/03/05 - 20050245475 - Functional and hyperfunctional sirna directed against bcl-2 Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rationale design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. ... 11/03/05 - 20050245474 - Double stranded constructs comprising one or more short strands hybridized to a longer strand The present invention provides compositions comprising an antisense oligomeric compound hybridized to at least one shorter sense oligomeric compound. The sense oligomeric compounds can be covalently linked to the antisense oligomeric compounds. At least a portion of the antisense oligomeric compound is complementary to and hybridizes with a nucleic acid ... 11/03/05 - 20050245473 - Proliferation- and differentiation-modulating agents and uses therefor The present invention discloses the use of E2F pathway modulators and optionally a differentiation stimulus in methods for treating or preventing conditions associated with the deregulation of epithelial cell proliferation and differentiation and for diagnosing the presence or risk of developing such conditions. ... 11/03/05 - 20050245472 - Engineered rnai adenovirus silencing expression (erase) of dna reair proteins The present invention relates to compositions and methods for killing cancer cells and treating subjects having cancer comprising administering small inhibitory RNAs (siRNA) specific for DNA repair proteins in conjunction with administration of conventional DNA-damaging agents such as radiation and chemotherapeutic agents. ... 11/03/05 - 20050245471 - Combination products for use in antitumoral treatment The invention concerns combination products comprising (i) at least a substance capable of inhibiting CSF-1 activity and/or at least a nucleic acid, comprising at least a sequence coding for a substance capable of inhibiting CSF-1 activity and (ii) at least a substance having a cytotoxic activity and/or at least a ... 10/27/05 - 20050239739 - Conjugates and compositions for cellular delivery This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules. ... 10/27/05 - 20050239738 - Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization The present invention is drawn to a method of suppressing the phenomenon of accelerated repopulation, i.e. the proliferation of cells upon exposure to a clinically relevant dose of radiation energy. More specifically, the invention provides a method of radiosensitizing cancer cells by administering an expressible nucleic acid molecule encoding a ... 10/27/05 - 20050239737 - Identification of molecular interaction sites in rna for novel drug discovery Methods of identifying molecular interaction sites in eukaryotic and prokaryotic nucleic acids, especially RNA, are described. Secondary structural elements are identified from highly conserved sequences. Methods of preparing databases relating to such molecular interaction sites are also provided herein as are databases themselves. Therapeutic, agricultural, industrial, and other applicability results ... 10/27/05 - 20050239736 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 10/27/05 - 20050239735 - Enhancement of immune responses The present invention provides methods for enhancing the immune responses induced by IRM compounds. Generally, the methods include administering a cytokine receptor agonist or a cytokine inducer prior to administering an IRM compound to a cell population. ... 10/27/05 - 20050239734 - C-class oligonucleotide analogs with enhanced immunostimulatory potency The invention relates to a class of CpG immunostimulatory oligonucleotides containing a CpG immunostimulatory motif and a second motif which is capable of forming secondary structure, including duplex and higher order structures, in vitro and in vivo. The oligonucleotides of the invention are useful as adjuvants in vaccination. The oligonucleotides ... 10/27/05 - 20050239733 - Sequence requirements for inhibitory oligonucleotides Novel oligonucleotides having immune inhibitory effects, and methods for their use, are provided. The inhibitory oligonucleotides include those that specifically inhibit certain Toll-like receptors, including TLR7, TLR8, and TLR9. Certain of the immunoinhibitory oligonucleotides inhibit a combination of TLRs selected from TLR7, TLR8, and TLR9. Inhibitors of TLR9 are characterized ... 10/27/05 - 20050239732 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 10/27/05 - 20050239731 - Rna interference mediated inhibition of map kinase gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating mitogen activated protein kinase (MAP kinase) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MAP ... 10/27/05 - 20050239730 - Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine The invention relates to Plasmodium falciparum Erythrocyte Binding Protein BAEBL for use as a vaccine. ... 10/27/05 - 20050239729 - Substances for preventing and treating autoimmune diseases A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the ... 10/27/05 - 20050239728 - Double stranded rna structures and constructs, and methods for generating and using the same The present invention relates to novel double stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as ... 10/27/05 - 20050239727 - Hyaluronic acid derivatives Derivatives between hyaluronic acid and at least one nitrogenated base, in particular at least one heterocyclic compound derived from purine and/or from pyrimidine and cosmetic and/or pharmaceutical compositions based on said derivatives. ... 10/20/05 - 20050234008 - Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide y gene The invention relates to methods for diagnosing a person's susceptibility for having an increased risk for the development of atherosclerosis and a diabetic person's susceptibility for having an increased risk for the development of diabetic retinopathy. The invention relates further to methods for treating persons diagnosed for having increased risk ... 10/20/05 - 20050234007 - Rna interference mediating small rna molecules Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like ... 10/20/05 - 20050234006 - Rna interference mediating small rna molecules Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like ... 10/20/05 - 20050234005 - Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus The inventive subject matter relates to a recombinant 110 kDa protein from O. tsutsugamuchi, Karp, Kato and Gilliam strains and for a DNA expression system containing DNA encoding the 110 kDa protein of O. tsutsugamuchi. The invention also relates to the use of these recombinant contructs in a formulation for ... 10/20/05 - 20050234004 - Compositions and methods of use of w-peptides The present invention relates to compositions and methods to modulating immune responses, such as those elicited by vaccination with W peptides. The compositions and methods are useful for, among other things, vaccine formulation for therapeutic and prophylactic vaccination (immunization) and for production of useful antibodies (e.g., monoclonal antibodies, for therapeutic ... 10/20/05 - 20050234003 - Method of using nucleic acid compositions for muting expression of a gene in animals The invention provides compositions and methods for muting expression of an endogenous gene in an animal, the muting resulting from providing a muting nucleic acid to cells in the animal. The muting nucleic acid comprises a transgene, which is substantially homologous to a portion of the endogenous gene. The portion ... 10/20/05 - 20050234002 - Antisense oligomers and methods for inducing immune tolerance and immunosuppression A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound containing 12-40 subunits and ... 10/20/05 - 20050234001 - Methods and compositions for modulating gluconeogenesis using pgc-1 The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as methods for identifying compounds that modulate the interaction of PGC-1 with PGC-1 target ... 10/20/05 - 20050234000 - Sirna delivery into mammalian nerve cells The present invention relates to methods of affecting expression of a target gene, suitably brain-derived neurotrophic factor (BDNF) or related genes in a nerve cell in the central nervous system of a mammal. The method includes formulating and delivering an siRNA composition to a target site on the mammal to ... 10/20/05 - 20050233999 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 10/20/05 - 20050233998 - Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating VEGF and/or VEGFR gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of VEGF and/or VEGFR gene ... 10/20/05 - 20050233997 - Rna interference mediated inhibition of matrix metalloproteinase 13 (mmp13) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating matrix metalloproteinase (e.g., MMP13) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of MMP13 gene expression ... 10/20/05 - 20050233996 - Rna interference mediated inhibition of hairless (hr) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating hairless (HR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of hairless gene expression and/or activity ... 10/20/05 - 20050233995 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 10/20/05 - 20050233994 - Methods and vectors for expressing sirna In a first aspect, the invention provides expression vectors comprising: (a) a first RNA polymerase III promoter operably associated with a first RNA polymerase III termination signal and (b) a second RNA polymerase III promoter operably associated with a second RNA polymerase III termination signal, wherein the first and second ... 10/20/05 - 20050233993 - Methods for promoting homologous recombination Nucleosomal polynucleotides promote homologous strand pairing by recombinase. In the absence of superhelical tension, the efficiency of strand pairing with nucleosomal polynucleotides is substantially higher than that with non-nucleosomal nucleic acids. In addition, a recombinase comprising Rad54 and Rad51 associated activity can function cooperatively in the ATP-dependent remodeling of a ... 10/20/05 - 20050233992 - Regeneration of endogeneous myocardial tissue by induction of neovascularization This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder. This invention further provides the instant ... 10/20/05 - 20050233991 - Methods and compositions for the identification, assessment, and therapy of small cell lung cancer The invention provides novel methods and compositions for modulating small cell lung cancer (SCLC) proliferation and metastasis through modulation of CXCR4 activity or expression. Also provided are methods for identifying compounds that modulate SCLC proliferation and metastasis through modulation of CXCR4 activity or expression. Further provided are methods for treating ... 10/20/05 - 20050233990 - Anti-cancer agents comprising disintegrin genes and the treating methods The present invention relates to liposome complex comprising a novel disintegrin, saxatilin, gene derived from Agkistrodon saxatilis and methods for curing and preventing tumors by transferring the complexes to a living body. ... 10/13/05 - 20050227940 - Amplifying interfering rna (rnai) expression and effects Methods for amplifying expression of interfering RNA (RNAi), and preferably siRNA or shRNA, using a RNAi (si/shRNA)-expressing concatamer, are disclosed. The methods are useful for modulating, including down-regulating and/or inhibiting, expression of a target gene in cells, including mammalian cells. ... 10/13/05 - 20050227939 - Modulation of kallikrein 6 expression Compounds, compositions and methods are provided for modulating the expression of kallikrein 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding kallikrein 6. Methods of using these compounds for modulation of kallikrein 6 expression and for diagnosis and treatment of disease associated with expression of kallikrein 6 are provided. ... 10/13/05 - 20050227938 - Antisense modulation of tfap2c expression Antisense compounds, compositions and methods are provided for modulating the expression of TFAP2C. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Methods of using these compounds for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided. ... 10/13/05 - 20050227937 - Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor. ... 10/13/05 - 20050227936 - Rna interference mediated inhibition of tgf-beta and tgf-beta receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating transforming growth factor beta (TGF-beta) and/or transforming growth factor beta receptor (TGF-betaR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other ... 10/13/05 - 20050227935 - Rna interference mediated inhibition of tnf and tnf receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways ... 10/13/05 - 20050227934 - Pancreatic islet microrna and methods for inhibiting same The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. ... 10/13/05 - 20050227933 - Treatment of bacterial induced diseases using dna methyl transferase inhibitors Methods for treating and/or preventing disease conditions caused or induced or aggravated by microbes, especially bacteria, by inhibiting DNA methyltransferase activity, such as by administering to an animal a DNA methyltransferase inhibitor, are disclosed, along with methods of reducing or ablating virulence in bacteria by inhibiting DNA methyltransferase activity. ... 10/06/05 - 20050222075 - Process for delivering nucleic acids to cardiac tissue A process for delivering a nucleic acid to a cardiac tissue cell in a mammal is described, comprising introducing a composition consisting of a nucleic acid to a blood vessel, which subsequently delivers the nucleic acid to the cardiac tissue cell. The nucleic acid can be DNA or RNA or ... 10/06/05 - 20050222074 - Modulators of bone homeostasis identified in a high-throughput screen The invention relates to the field of molecular genetics and medicine. In particular, the present invention relates to the field of functional genomics, i.e., to a method for the identification of genes that function in regulating bone homeostasis, such as the induction of osteogenesis. In particular, the present invention relates ... 10/06/05 - 20050222073 - Antisense modulation of thyroid hormone receptor interactor 6 expression Antisense compounds, compositions and methods are provided for modulating the expression of thyroid hormone receptor interactor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding thyroid hormone receptor interactor 6. Methods of using these compounds for modulation of thyroid hormone receptor interactor 6 expression and ... 10/06/05 - 20050222072 - Potent mucosal immune response induced by modified immunomodulatory oligonucleotides The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining. ... 10/06/05 - 20050222071 - Topical administration of at least one double-stranded rna oligonucleotide (dsrna) Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically ... 10/06/05 - 20050222070 - Pancreas-specific proteins The present invention discloses polynucleotides which identify and encode DP119, DP444, DP810, DP685, WE474, DP160, RA977, or RA770 as well as novel functions for these proteins of the inventions. The invention provides for compositions for disorders associated with the expression of the proteins of the invention, such as for the ... 10/06/05 - 20050222069 - Optimization of immunomodulatory properties of genetic vaccines This invention provides methods for obtaining molecules that can modulate an immune response, and immunomodulatory molecules obtained using the methods. The molecules find use, for example, in the tailoring of an immune response induced by a genetic vaccine for a desired purpose. ... 10/06/05 - 20050222068 - Method and antisense composition for selective inhibition of hiv infection in hematopoietic cells A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective ... 10/06/05 - 20050222067 - Dna virus microrna and methods for inhibiting same The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules. ... 10/06/05 - 20050222066 - Rna interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating VEGF and/or VEGFR gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of VEGF and/or VEGFR gene ... 10/06/05 - 20050222065 - Vascular therapeutics The present invention provides a method of preventing or reducing restenosis, neointima formation, graft failure, atherosclerosis, angiogenesis and/or solid tumour growth in a subject. The method comprises administering to the subject a prophylactically effective dose of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or ... 10/06/05 - 20050222064 - Polycationic compositions for cellular delivery of polynucleotides The present invention relates to delivery of biologically active molecules to cells. Specifically, the invention relates to polycationic compositions, polymers and methods for delivering nucleic acids, polynucleotides, and oligonucleotides such RNA, DNA and analogs thereof, including short interfering RNA (siRNA), ribozymes, and antisense, or peptides, polypeptides, proteins, antibodies, hormones and ... 10/06/05 - 20050222063 - Methylenetetrahydrofolate reductase inhibitors and use thereof The present invention provides methylenetetrahydrofolate reductase (MTHFR) inhibitors, such as antisense oligonucleotides, for use in selective inhibition of cancer cell growth in a mammal. The present invention further provides methods of using the MTHFR inhibitors, alone or in combination with one or more standard chemotherapeutics, for selective inhibition of cancer ... 10/06/05 - 20050222062 - Decoy for treating and/or preventing th2 cytokine-associated allergic disease, gata3 mutant protein and medicinal compositions containing the same The present invention provides GATA3 decoys and GATA3 mutant proteins which can specifically suppress Th2 cytokine production and pharmaceutical compositions comprising such decoys and mutant proteins. This suppression is achieved by inhibiting binding of the GATA3 protein to the low affinity GATA3 binding sequence within the Th2 cytokine gene cluster, ... 10/06/05 - 20050222061 - Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye, wherein a composition comprising one or more doubled stranded oligoribonucleotides (dsRNA) is introduced into the cell, tissue or organism outside the blood-brain or blood-retina barriers. Furthermore, a ... 10/06/05 - 20050222060 - Compositions and methods to initiate or enhance antibody and major-histocompatibility class i or class ii-restricted t cell responses by using immunomodulatory, non-coding rna motifs The present application is directed to non-coding RNA motifs that are used in conjunction with an antigen or without an antigen to induce, enhance or modulate an immune response that comprises a B cell and a T cell component. ... 10/06/05 - 20050222059 - Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer The invention relates to antibodies and ribozymes that target EGFRvIII and the use to treat breast cancer. ... 10/06/05 - 20050222058 - Antisense modulation of mucin 1, transmembrane expression Antisense compounds, compositions and methods are provided for modulating the expression of mucin 1, transmembrane. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding mucin 1, transmembrane. Methods of using these compounds for modulation of mucin 1, transmembrane expression and for treatment of diseases associated with ... 10/06/05 - 20050222057 - Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic ... 09/29/05 - 20050215509 - Method for inhibiting jnk-1 kinase activity by scca The present invention provides a method and composition that inhibit the kinase activity of JNK-1 (c-Jun N-terminal kinase 1) in cells by increasing the expression of squamous cell carcinoma antigen (SCCA) in cells. ... 09/29/05 - 20050215508 - Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef Pharmaceutical compositions which comprise HIV Nef DNA vaccines are disclosed, along with the production and use of these DNA vaccines. The nef-based DNA vaccines of the invention are administered directly introduced into living vertebrate tissue, preferably humans, and express the HIV Nef protein or biologically relevant portions thereof, inducing a ... 09/29/05 - 20050215507 - Therapeutic anti-cancer dna Aspects of the invention relate to nucleic acids molecules that are useful for specifically destroying selected cells, tissues, or organs. Aspects of the invention are useful for treating diseases (e.g., cancer) that affect specific cells, tissues, or organs. ... 09/29/05 - 20050215506 - Modulation of tyrosinase expression Compounds, compositions and methods are provided for modulating the expression of tyrosinase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding tyrosinase. Methods of using these compounds for modulation of tyrosinase expression and for diagnosis and treatment of disease associated with expression of tyrosinase are provided ... 09/29/05 - 20050215505 - Design and therapeutic use of adpase enhanced apyrases The present invention provides for design and therapeutic use of ADPase enhanced polypeptides, pharmaceutical compositions, and methods useful for preventing and reversing platelet aggregation and recruitment for the treatment and prevention of vascular disorders in mammals. ... 09/29/05 - 20050215504 - Antisense modulation of sterol regulatory element-binding protein-1 expression Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of ... 09/29/05 - 20050215503 - Hif oligonucleotide decoy molecules The invention concerns double-stranded HIF decoy oligodeoxynucleotide (dsODN) molecules comprising a core sequence that is capable of specific binding to a HIF transcription factor, compositions containing such molecules, and their use in the treatment of various diseases and pathologic conditions associated with the regulation of gene transcription by a HIF ... 09/29/05 - 20050215502 - Regulation of endogenous gene expression in cells using zinc finger proteins The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins. ... 09/29/05 - 20050215501 - Methods and products for enhancing epitope spreading The invention relates to methods for inducing epitope specific immune responses by combining an immunostimulant therapy with a therapeutic protocol. ... 09/29/05 - 20050215500 - Immunostimulatory nucleic acid molecules Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed. ... 09/29/05 - 20050215499 - Lipoproteins as nucleic acid vectors The present invention relates to materials and methods for the in vivo transport and deliver of nucleic acids. More particularly, it concerns the use of lipoproteins, including but not limited to, low density lipoproteins (“LDL”), and/or apolipoproteins for the binding and in vivo transport of nucleic acids. In addition, the ... 09/29/05 - 20050215498 - Method for the protection of endothelial and epithclial cells during chemotherapy The present invention is directed to the use of a protective oligodeoxyribonucleotide for the treatment of a patient undergoing treatment with an immunosuppressant. The invention is further directed to a pharmaceutical composition containing a therapeutically effective dose of an immunosuppressant and of a protective oligodeoxyribonucleotide. ... 09/29/05 - 20050215497 - Inhibitor oligonucleotides and their use for specific repression of a gene The invention concerns a double-stranded oligonucleotide characterized in that it consists of two complementary oligonucleotide sequences forming a hybrid comprising each at one of their 3′ or 5′ ends one to five non-matched nucleotides forming single-stranded ends overlapping from the hybrid, one of said oligonucleotide sequences being substantially complementary of ... 09/22/05 - 20050209184 - Oligodeoxynucleotide and its use to induce an immune response wherein the central CpG motif is unmethylated, Pu is a purine nucleotide, Py is a pyrimidine nucleotide, X and W are any nucleotide, M is any integer from 0 to 10, and N is any integer from 4 to 10. Methods of using these oligodeoxynucleotides to induce an immune response ... // - 5′ X1X2X3Pu1 Py2 CpG Pu3 Py4X4X5X6(W)M(G)N-3′ - ... 09/22/05 - 20050209183 - Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated cpg motifs Embodiments of the present invention provide methods for the prophylaxis and/or treatment of epithelial integument with inflammatory changes that comprise administering to a patient suffering from such a disorder a pharmaceutically acceptable amount of a nucleic acid comprising a non-methylated CpG motif. Other aspects of the invention relate to cosmetic ... 09/22/05 - 20050209182 - Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity The present invention relates to nucleic acid aptamers that bind to bacterial proteases such as CylA and methods for their use alone or in combination with other therapies, such as antibiotics. Also disclosed are nucleic acids such as siRNA, antisense, and enzymatic nucleic acid molecules that can modulate the expression ... 09/22/05 - 20050209181 - Compositions and methods for diagnosing and treating mental disorders The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. ... 09/22/05 - 20050209180 - Rna interference mediated inhibition of hepatitis c virus (hcv) expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating HCV gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of HCV gene expression and/or activity by ... 09/22/05 - 20050209179 - Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating beta-secretase (BACE), amyloid precurson protein (APP), PIN-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity ... 09/22/05 - 20050209178 - Methods and compositions for the treatment of obesity The present invention provides novel compositions containing a SCA-2 therapeutic element, which is involved in the regulation normal body weight and may be administered for the prevention of an abnormal accumulation of body fat. In particular the compositions and methods of the present invention may be used for the prevention ... 09/22/05 - 20050209177 - Combined therapeutical treatment of hyperproliferative diseases A medicinal combination of one or more nucleic acids that at least partially inhibit oncogenic cell signalling pathways, and a therapeutic anticancer agent, for use simultaneous, separate or over a period of time to treat hyperproliferative diseases. ... 09/15/05 - 20050203050 - Hkis compositions and methods of use Disclosed herein are novel composition and methods for altering the proliferation of a cell. Included are wild-type and mutant hKIS polypeptides along with cyclin kinase inhibitors containing mutations that prevent their inhibition with serine/threonine kinases. ... 09/15/05 - 20050203049 - 47169 and 33935, novel human glycosyl transferases and uses therefor The invention provides isolated nucleic acids molecules, designated 47169 and 33935 nucleic acid molecules, which encode novel glycosyl transferases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47169 and 33935 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic ... 09/15/05 - 20050203048 - Human leucine-rich repeat containing protein expressed predominately in bone marrow, hlrrbm1 The present invention provides novel polynucleotides encoding HLRRBM1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HLRRBM1 polypeptides to the diagnosis, treatment, and/or prevention ... 09/15/05 - 20050203047 - Delivery vectors for short interfering rna, micro-rna and antisense rna This invention relates to compositions and methods for transcription and expression of nucleic acids into organisms. In particular, the invention comprises a tRNA vector system to deliver and express short interfering nucleic acid, small interfering (siRNA) and micro RNA (miRNA) and antisense (asRNA) into an organism with high efficiency. The ... 09/15/05 - 20050203046 - Methods of modulating a mammalian cytokine Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor. ... 09/15/05 - 20050203045 - Antisense modulation of cellular inhibitor of apoptosis-2 expression Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression and for treatment of ... 09/15/05 - 20050203044 - Small-mer compositions and methods of use The present invention concerns small-mer compositions and methods useful in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small-mer compositions capable of inhibiting viral replication, useful in treating diseases and conditions related to viral infection, and/or capable of ... 09/15/05 - 20050203043 - Identification of toxic nucleotide sequences Toxic nucleic acid sequences and methods for identifying, using, and screening libraries for them, including in silico screening, are provided. Compositions of the invention comprise unimolecular and double stranded polynucleotides comprising at least one toxicity region. Toxic sequences of the invention include A/G UUU A/G/U, G/C AAA G/C, and/or GCCA, ... 09/15/05 - 20050203042 - Oligomeric compounds for the modulation of bcl-2 The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging ... 09/15/05 - 20050203041 - Antisense compound and method for selectively killing activated t cells A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of ... 09/15/05 - 20050203040 - Rna interference mediated inhibition of vascular cell adhesion molecule (vcam) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating vascular cell adhesion molecule gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of vascular cell adhesion ... 09/15/05 - 20050203039 - Novel endonuclease of immune cell, process for producing the same and immune adjuvant using the same The present invention relates to a novel endonuclease enzyme which is secreted from immune cell and recognizes bacterial DNA as foreign agent and processes it to produce about 10 bp single-stranded oligonucleotide including CpG motif which is involved in immune response. Also, the present invention relates to a process for ... 09/15/05 - 20050203038 - Modulation of ace2 expression Compounds, compositions and methods are provided for modulating the expression of ACE2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding ACE2. Methods of using these compounds for modulation of ACE2 expression and for diagnosis and treatment of diseases and conditions associated with expression of ACE2 are provided. ... 09/15/05 - 20050203037 - Complex immuno-gene medical composition for inhibiting tumor cells Disclosed is a complex immuno-gene medical composition activating NK cells to enhance host immune system. The composition is usage of a combination of a plurality of cytokines, combined usage of the kinds of Th1 and Th2 cytokines. Th2 cytokine antagonizes TGF-β inhibiting NK cells to disable the inhibition of immune ... 09/15/05 - 20050203036 - Compositions and methods for treating hematologic malignancies and multiple drug resistance Methods and compositions are provided for treating a subject having or at risk of developing a hematologic malignancy and/or multiple drug resistance. ... 09/08/05 - 20050197315 - Sirna expression system and method for producing functional gene knock-down cell using the system The in vivo siRNA expression system according to this invention is a system that intracellularly expresses small interfering (si) RNAs and comprises antisense and sense code DNAs coding for antisense and sense RNAs targeting any region of a target gene mRNA and one or more promoters that function to express ... 09/08/05 - 20050197314 - Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto. ... 09/08/05 - 20050197313 - Multiple promoter expression cassettes for simultaneous delivery of rnai agents The present invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo. ... 09/08/05 - 20050197312 - Transcription factor rna interference reagents and methods of use thereof The present invention concerns methods and reagents useful in modulating transcription factor gene expression in a variety of applications, including methods of use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siRNA), short interfering ... 09/08/05 - 20050197311 - Compositions and methods for detecting intracellular glucose and analogs thereof The subject invention pertains to nucleic acid constructs for post-transcriptional control of expression of a polynucleotide encoding a protein in a cell, wherein the constructs include a metabolite responsive instability element such as the glucose-regulated mRNA instability element. The subject invention further pertains to host cells and vectors comprising the ... 09/08/05 - 20050197310 - Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The ... 09/08/05 - 20050197309 - Antisense modulation of dual specific phosphatase 5 expression Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding dual specific phosphatase 5. Methods of using these compounds for modulation of dual specific phosphatase 5 expression and for treatment of ... 09/08/05 - 20050197308 - Vaccines The present invention relates to efficient devices for administration of pharmaceutical agents into the skin of the human body. In particular the present invention provides devices for vaccination into the skin. The present invention provides a pharmaceutical agent delivery device having skin-piercing portion comprising a solid reservoir medium containing the ... 09/08/05 - 20050197307 - Compounds and methods for treating and screening viral reactivation This invention relates to host cellular factors as therapeutic and diagnostic compounds, and methods using such factors for screening for antiviral compounds, particularly compounds useful to treat Herpes virus infections, such as HSV-1 and HSV-2 infections. ... 09/08/05 - 20050197306 - Dna vaccines encoding heat shock proteins The present invention is related to recombinant constructs encoding heat shock proteins or active fragments thereof that are effective in treating T cell mediated inflammatory autoimmune diseases by DNA vaccines. The treatment with the recombinant constructs of the present invention provides long-term expression of specific heat shock proteins for fragments ... 09/08/05 - 20050197305 - Methods and compositions for blocking progression of a disease state The invention includes a reverse polarity 8-aminopurine substituted oligonucleotide hairpin (parallel-stranded hairpin) referred to herein as RP8AP hairpin. Application of the invention to a biological system in a disease state results in the possible interference with a disease causing agent in a number of potential ways, for example, through interference ... 09/08/05 - 20050197304 - Nucleic acid therapy to enhance cartilage repair The present invention relates to the application of nucleic acid therapy for the repair and regeneration of cartilage. The invention encompasses the introduction of naked DNA encoding bioactive agent(s), whose expression stimulates and otherwise facilitates the repair and regeneration of cartilage. The present invention provides DNA constructs for introduction to ... 09/01/05 - 20050192242 - Therapeutic fusion protein transgenes Chimeric antitumor compounds for the treatment of cancer are disclosed. The chimeric compounds may be encoded by a nucleic acid. Delivery of the nucleic acid to cells in vivo provides for in vivo production of the antitumor compounds. ... 09/01/05 - 20050192241 - Compositions and methods for the systemic treatment of arthritis The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. ... 09/01/05 - 20050192240 - Methods and compositions relating to expression factors The invention describes an expression factor and methods for inhibiting the growth of cells, for enhancing the activity of a drug, and for inhibiting the virulence of microbes. Methods of screening for expression factor inhibitors are also described. The compositions comprise at least one expression factor inhibitor and may further ... 09/01/05 - 20050192239 - Methods for identifying risk of breast cancer and treatments thereof Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments ... 09/01/05 - 20050192238 - Modulation of the expression of genes dependent on stat-1 The present invention relates to decoy-oligonucleotides and antisense-oligonucleotides having the nucleic acid sequence according to SEQ ID NO: 1 to 43 as well as the use thereof as medicaments. ... 09/01/05 - 20050192237 - Antisense antibacterial cell division composition and method Antisense oligomers directed to bacterial cell division and cell cycle-encoding nucleic acids are capable of selectively modulating the biological activity thereof, and are useful in treatment and prevention of bacterial infection. The antisense oligomers are substantially uncharged, and contain from 8 to 40 nucleotide subunits, including a targeting nucleic acid ... 08/25/05 - 20050187180 - Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna The present invention is directed to the identification and use of ribonucleoside analogs to induce the mutation of an RNA virus, including BVDV, HIV and HCV, or a virus which otherwise replicates through an RNA intermediate. The increase in the mutation rate of the virus results in reduced viability of ... 08/25/05 - 20050187179 - Apoptosis inducing agents and methods Methods and compositions are disclosed for inducing differentiation and apoptosis in cells that overexpress Notch proteins. A cell fate determining function of Notch is specifically disrupted at a time when the cell is undergoing differentiation, which causes the cell to undergo apoptosis. The invention includes therapies for tumors that overexpress ... 08/25/05 - 20050187178 - Compositions comprising alternating 2'-modified nucleosides for use in gene modulation The present invention provides compositions comprising at least one oligomeric compound comprising an alternating motif and further include a region that is complementary to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments ... 08/25/05 - 20050187177 - Directed apoptosis in cox-2 overexpressing cancer cells through expression targeted gene delivery The present invention provides methods and constructs for selectively expressing an Apoptosis-Inducing Gene (AIG) in a population of cells that overexpress cyclooxygenase-2 (COX-2) to induce apoptosis in the cell. To achieve this goal a chimeric gene construct is used that comprises a cyclooxygenase-2 promoter (COX-2 promoter) that is operably linked ... 08/25/05 - 20050187176 - Method for inhibiting nf-kappa b signaling and use to treat or prevent human diseases Methods of treating inflammation in a patient comprise administering to the patient a composition comprising a GRO. ... 08/25/05 - 20050187175 - Methods and compositions for cpg15-2 Disclosed herein are compositions of CPG15-2 and methods for treating conditions of excessive cell death, such as neurological conditions, using such compositions. Compounds that inhibit the activity of CPG15-2 are also disclosed herein for the treatment of conditions of undesirable cell survival, such as cancer. ... 08/25/05 - 20050187174 - Rna interference mediated inhibition of intercellular adhesion molecule (icam) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ICAM gene expression ... 08/25/05 - 20050187173 - A method of delaying the onset of diabetes A method for preventing, delaying the onset of or treating diabetes in a patient comprising selecting a patient who is susceptible to developing diabetes, who is developing diabetes or who is diabetic and administering to the patient one or more than one dose of a pharmaceutical agent comprising a polynucleotide ... 08/18/05 - 20050182017 - Immunostimulatory nucleic acid molecules Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant. ... 08/18/05 - 20050182016 - Collapsin response mediator protein-1 (crmp-1) transcriptional regulatory nucleic acid sequences This invention provides a transcription unit which is isolated from the upstream nucleic acid sequence of the collapsing response mediator protein-1 (CRMP-1) gene, an invasion-suppressor gene. The transcription unit contains a nucleic acid regulatory sequence which demonstrates promoter and/or regulatory activities (such as providing a transcription factor binding site) to ... 08/18/05 - 20050182015 - Antisense modulation of eif2c1 expression Antisense compounds, compositions and methods are provided for modulating the expression of EIF2C1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EIF2C1. Methods of using these compounds for modulation of EIF2C1 expression and for treatment of diseases associated with expression of EIF2C1 are provided. ... 08/18/05 - 20050182014 - Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation One aspect of the current invention is a method of preventing and/or treating arthritis and/or preventing or treating lameness in a subject. Additionally, subject quality of life and welfare, and body condition scores are improved by utilizing methodology that administers the nucleic acid expression construct encoding a GHRH or functional ... 08/18/05 - 20050182013 - Intravascular delivery of nucleic acid Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic ... 08/18/05 - 20050182012 - Nf-kappab oligonucleotide decoy molecules The present invention concerns double-stranded NF-κB decoy oligodeoxynucleotide (NF-κB dsODN) molecules that contain a core sequence capable of specific binding to an NF-κB transcription factor. In a particular aspect, the invention concerns NF-κB decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention ... 08/18/05 - 20050182011 - Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure The present invention provides methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2, NF-AT3, calcineurin, MCIP, and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of many of these factors or the pathways mediated by these factors ... 08/18/05 - 20050182010 - Antiviral therapy on the basis of rna interference The invention concerns a gene therapy for treatment of animals and humans which suffer from an infection with a chronic virus such as HIV or HCV. It can also be used prophylactically to prevent chronic infection. The therapy makes use of a nucleotide construct stably integrated in the genome of ... 08/18/05 - 20050182009 - Rna interference mediated inhibition of nf-kappa b / rel-a gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating NF-kappa B, REL-A, REL-B, REL, NKkappaB1, or NFkappaB2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways ... 08/18/05 - 20050182008 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO ... 08/18/05 - 20050182007 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin ... 08/18/05 - 20050182006 - Rna interference mediated inhibition of protein kinase c alpha (pkc-alpha) gene expression using short interfering nucleic acid (sina) This invention relates to compounds, compositions, and methods useful for modulating PKC alpha gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PKC alpha gene expression and/or ... 08/18/05 - 20050182005 - Anti-microrna oligonucleotide molecules The invention relates to isolated anti-microRNA molecules. In another embodiment, the invention relates to an isolated microRNA molecule. In yet another embodiment, the invention provides a method for inhibiting microRNP activity in a cell. ... 08/18/05 - 20050182004 - Modulation of dc-sign expression Compounds, compositions and methods are provided for modulating the expression of DC-SIGN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DC-SIGN. Methods of using these compounds for modulation of DC-SIGN expression and for diagnosis and treatment of diseases and conditions associated with expression of DC-SIGN are provided. ... 08/18/05 - 20050182003 - Drugs to be used in gene therapy for recessively transmitted genetic disease The present invention provides a remedy to be used in gene therapy that can suppress immune response to a transgene product in gene therapy of genetic diseases such as recessive genetic diseases, or a method for treating genetic diseases such as recessive genetic diseases with the use of the remedy ... 08/18/05 - 20050182002 - Agents which interact with a serotonin transporter for the treatment of cancer The present invention relates to a method of inducing cell death in a neoplastic cell expressing a serotonin transporter (SERT) such as Burkitt's lymphoma cell or a chronic lymphocytic leukaemia cell. The method comprising exposing said neoplastic cell to a therapeutically effective amount of a pharmaceutically active agent which interacts ... 08/11/05 - 20050176672 - Use of cationic lipids to generate anti-tumor immunity A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides ... 08/11/05 - 20050176671 - 22437, a novel human sulfatase and uses therefor The invention provides isolated nucleic acids molecules, designated 22437 nucleic acid molecules, which encode a novel sulfatase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 22437 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a ... 08/11/05 - 20050176670 - Recombinant dna for gene suppression Anti-sense-oriented RNA gene suppression agents in the form of a loop of anti-sense-oriented RNA is produced in cells of transgenic organisms, e.g. plants, by transcription from a recombinant DNA construct which comprises in 5′ to 3′ order a promoter element operably linked to an anti-sense-oriented DNA element and a complementary ... 08/11/05 - 20050176669 - Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence The invention provides methods for predicting whether an ovarian cancer patient's tumor wi |